P F -[ADDRESS_455820] N u m ber : P F -[ADDRESS_455821] N a me: N ot A p plica ble ( N/ A )
Unite d St ates ( U S) In vesti g ati o n al Ne w 
Dr u g (I N D) N u m ber: 
E ur o pe a n Cli nic al Tri al sD at a b ase 
( E u dr a C T) N u m ber: N/ A 
Pr ot oc ol N u m ber: C 3 9 9 1 0 0 2 
P h as e: 1
S h ort Title: A P hase 1 St u d y of M ulti ple Escalati n g Oral D oses of 
P F -0 7 0 8 1 5 3 2 i n A d ult Partici pa nts Wit h T y pe 2 Dia betes Mellit u s
T his d oc u me nt a n d acc o m pa n yi n g materials c o ntai n c o nfi de ntial i nf or mati o n bel o n gi n g t o [COMPANY_007].  E xce pt as 
ot her wise a gre e d t o i n wr iti n g, b y acce pti n g or re vie wi n g t hese d oc u me nt s, y o u a gree t o h ol d t his i nf or mati o n i n 
c o nfi de nce a n d n ot c o p y or discl ose it t o ot hers (e xce pt w here re q uire d b y a p plica ble la w ) or use it f or 
u na ut h orize d p u r p oses.  I n t he e ve n t of an y act ual o r s us p ecte d breac h of t his o bli gati o n, [COMPANY_007] m ust be 
pr o m ptl y n otifie d .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary of Changes and Rationale
Original protocol 16 January 2020 Not applicable (N/A)090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 3T A B L E O F C O N T E N T S 
LI S T O F T A B L E S ................................ ................................ ................................ ..................... 8
1. P R O T O C O L  S U M M A R Y ................................ ................................ ..................................... 9 
1. 1. S y n o p sis ................................ ................................ .................................................... 9 
1. 2. Sc he ma ................................ ................................ ...................................................... 9 
1. 3. Sc he d ule of Acti vities ( S o A) ................................ ................................................... [ADDRESS_455822] u d y  Rati o nale ................................ ................................ ....................................... 1 7 
2. 2. Bac k gr o u n d ................................ ................................ ............................................. 1 7 
2. 2. 3. N o ncli nical Safet y................................ ...................................................... 1 9 
2. 2. 4. Cli nical E x perie nce wit h P F -0 7 0 8 1 5 3 2...................................................... 2 0 
2. 3. Be nefit/ Ris k Assess me nt ................................ ......................................................... [ADDRESS_455823] u d y  Desi g n ................................ ..................................... 2 7 
4. 2. 1. P o p ulat i o n(s) ................................ ............................................................... [ADDRESS_455824] u d y  Bli n di n g ................................ ............................................................ 2 8 
4. 2. 4. E n d p oi nts ................................ ................................ .................................... 2 8 
4. 2. 4. 1. Safet y................................ ......................................................... 2 8 
4. 2. 4. 2. C haracterizati o n of P F -0 7 0 8 1 5 3 2 P har mac o ki netics................ 2 9 
4. 3. J ustificati o n f or D ose ................................ .............................................................. 3 0 
4. 3. 1. D ose Selecti o n -- Part A ................................ ................................ ............. 3 1 
4. 3. 2. D ose Selecti o n -- Part B ................................ ................................ ............. 3 1 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI C CI 
C CI 
P F -[ADDRESS_455825] u d y  I nter ve nti o n(s) A d mi nistere d ................................ ........................................ 4 3 
6. 1. 1. A d mi nistrati o n ................................ ............................................................ 4 3 
6. 2. Pre parati o n/ Ha n dli n g/ St ora ge/ Ac c o u nta bilit y ........................................................ 4 4 
6. 2. 1. Pre parati o n a n d Dis pe nsi n g ................................ ........................................ 4 6 
6. 3. Meas ures t o Mi ni mize Bias: Ra n d o mizati o n a n d Bli n di n g ..................................... [ADDRESS_455826] u d y  I nter ve nti o n C o m plia nce ................................ ............................................... 4 8 
6. 5. C o nc o mita nt T hera p y ................................ .............................................................. 4 8 
6. 5. 1. Me dicati o ns f or Gl yce mic C o ntr ol: Parts A a n d C o nl y ............................. 4 8 
6. 5. 2. A nti h y perte nsi ve a n d L i pi d -M o dif y i n g A ge nts: Parts A, B, a n d C ........... [ADDRESS_455827] o p pi n g R ules ................................ .......................... 5 1 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455828] u d y ................................ .................................. 5 3 
7. DI S C O N TI N U A TI O N O F S T U D Y I N T E R V E N TI O N A N D P A R TI CI P A N T 
DI S C O N TI N U A TI O N/ WI T H D R A W A L ................................ ........................................... [ADDRESS_455829] u d y  I nter ve nti o n ................................ ................................ .... 5 3 
7. 2. Partici pa nt Disc o nti n uati o n/ Wit h dra wal Fr o m t he St u d y ....................................... [ADDRESS_455830] t o F oll o w u p ................................ ................................ .................................... 5 6 
8. S T U D Y A S S E S S M E N T S A N D P R O C E D U R E S............................................................... 5 6 
8. 1. Efficac y  Assess me nts ................................ .............................................................. 5 9 
8. 2. Safet y Assess me nts ................................ ................................ ................................ .5 9 
8. 2. 1. P h y sical E xa mi nati o ns ................................ ................................................ 5 9 
8. 2. 2. Vital Si g ns ................................ ................................ .................................. 5 9 
8. 2. 3. Electr ocar di o gra ms ................................ ..................................................... 6 0 
8. 2. 4. Cli nical Safet y  L a b orat or y Assess me nts .................................................... 6 0 
8. 2. 4. 1. Fasti n g Fi n gerstic k Bl o o d Gl uc ose ( v ia Gl uc o meter) ............... 6 1 
8. 2. 4. 2. H y p o gl yc e mia Re p orti n g .......................................................... 6 2 
8. 3. A d verse E ve nts a n d Seri o us A d verse E ve nts .......................................................... 6 3 
8. 3. 1. Ti me Peri o d a n d Fre q ue nc y  f or C ollecti n g A E a n d S A E I nf or mati o n ....... 6 3 
8. 3. 1. 1. Re p orti n g S A Es t o [COMPANY_007] Safet y ............................................... 6 3 
8. 3. 1. 2. Rec or di n g N o nseri o us A Es a n d S A Es o n t he C R F ................... 6 4 
8. 3. 2. Met h o d of Detecti n g A Es a n d S A Es .......................................................... 6 4 
8. 3. 3. F oll o w -u p of A Es a n d S A Es ................................ ....................................... 6 4 
8. 3. 4. Re g ulat or y  Re p orti n g Re q uire me nts f or S A Es ........................................... 6 4 
8. 3. 5. E x p os ure D uri n g Pre g na nc y  or Breastfee di n g, a n d O cc u pati o nal 
E x p os ure ................................ ................................ ................................ .......... 6 5 
8. 3. 5. 1. E x p os ure D uri n g Pre g na nc y ...................................................... 6 5 
8. 3. 5. 2. E x p os ure D uri n g Breastfee di n g ................................................ 6 5 
8. 3. 5. 3. Occ u pati o nal E x p os ure ............................................................. 6 5 
8. 3. 6. Me dicati o n Err ors ................................ ....................................................... 6 5 
8. 4. Treat me nt of O ver d ose ................................ ............................................................ 6 6 
8. 5. P har mac o ki netics ................................ ................................ .................................... 6 7 
8. 5. 1. Plas ma f or A nal ys is of P F -0 7 0 8 1 5 3 2......................................................... 6 7 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 68. 5. 3. Uri ne f or A nal ys is of P F - 0 7 0 8 1 5 3 2 ........................................................... 6 8 
8. 6. 3. B o d y Wei g ht ................................ ............................................................... 7 0 
8. 9. Healt h Ec o n o mics ................................ ................................ ................................... 7 2 
9. S T A TI S TI C A L C O N SI D E R A TI O N S ................................ ................................................ 7 2 
9. 1. Statistical H y p ot heses ................................ ............................................................. 7 3 
9. 2. Sa m ple Size Deter mi nati o n ................................ ..................................................... 7 3 
9. 3. P o p ulati o ns f or A nal y sis ................................ ......................................................... 7 3 
9. 4. Statistical A nal y ses ................................ ................................ ................................ .7 4 
9. 4. 1. Efficac y  A nal ys es ................................ ....................................................... 7 4 
9. 4. 2. Safet y A nal ys es ................................ .......................................................... 7 4 
9. 4. 2. 1. Electr ocar di o gra m A nal y s e s...................................................... 7 5 
9. 4. 3. P har mac o ki netic A nal y ses ................................ .......................................... 7 5 
9. 4. 3. 1. P F -0 7 0 8 1 5 3 2 P har mac o ki netics ................................................ 7 5 
9. 5. I nteri m A nal ys es ................................ ................................ ..................................... 7 9 
9. 5. 1. Data M o nit ori n g C o m mittee ................................ ................................ ....... 7 9 
1 0. S U P P O R TI N G D O C U M E N T A TI O N A N D O P E R A TI O N A L 
C O N SI D E R A TI O N S.......................................................................................................... 8 0 
1 0. 1. A p pe n di x 1: Re g ulat or y , Et hical, a n d St u d y  O versi g ht C o nsi derati o ns ............... 8 0 
1 0. 1 . 1. Re g ulat or y a n d Et hical C o nsi derati o ns ................................ .................... 8 0 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI 
P F -[ADDRESS_455831] u d y  a n d Site Cl os ure ................................ .............................................. 8 5 
1 0. 1. 8. P u blicati o n P olic y ................................ ..................................................... 8 6 
1 0. 1. 9. S p o ns or’s Q ualifie d Me dical Pers o n nel ................................................... 8 6 
1 0. 2. A p pe n di x 2: Cli nical La b orat or y  Tests ................................ ................................. 8 8 
1 0. 3. A p pe n di x 3: A d verse E ve nts: Defi niti o ns a n d Pr oce d ures f or Rec or di n g, 
E val uati n g, F oll o w -u p, a n d Re p orti n g ................................ ...................................... 9 0 
1 0. 3. 1. Defi niti o n of A E ................................ ....................................................... 9 0 
1 0. 3. 2. Defi niti o n of S A E ................................ ..................................................... 9 1 
1 0. 3. 3. Rec or di n g/ Re p orti n g a n d F oll o w -u p of A Es a n d/ or S A Es ....................... 9 2 
1 0. 3. 4. Re p orti n g of S A Es ................................ .................................................... 9 5 
1 0. 4. A p pe n di x 4: C o ntrace pti v e G ui da nce a n d C ollecti o n of Pre g na nc y  
I n f or mati o n ................................ ................................ ................................................ 9 6 
1 0. 4. 1. Male Partici pa nt Re pr o d ucti ve I ncl usi o n Criteria .................................... 9 6 
1 0. 4. 2. Fe male Par tici pa nt Re pr o d ucti ve I ncl usi o n Criteria ................................. 9 6 
1 0. 4. 3. W o ma n of C hil d beari n g P ote ntial ( W O C B P) .......................................... 9 6 
1 0. 4. 4. C o ntrace pti o n Met h o ds ................................ ............................................. 9 7 
1 0. 6. A p pe n di x 6: L i ver Safet y : S u g geste d Acti o ns a n d F oll o w -u p Assess me nts ...... 1 0 2 
1 0. 7. A p pe n di x 7: E C G Fi n di n gs of P ote ntial Cli nical C o ncer n ................................. 1 0 4 
1 0. 8. A p pe n di x 8: A b bre viati o ns ................................ ................................................. 1 0 6 
1 1. R E F E R E N C E S ................................ ................................ ................................................ 1 1 1 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 8LI S T O F T A B L E S 
Ta ble 1. Part A ( 4 -wee k i n T 2 D M): O verall Visit Sc he d ule a n d List of 
Pr oce d ures ( use wit h Ta ble 2 f or f ull detail s) ........................................... 1 1 
Ta ble 2. Part A ( 4 -wee k i n T 2 D M): Detaile d Sc he d ule (selecte d st u d y  da y s) ....... 1 2 
Ta ble 3. Part B ( 6 -wee k i n O bese): O verall Visit Sc he d ule a n d L ist of 
Pr oce d ures ( use wit h Ta ble 4 f or f ull details) ........................................... 1 3 
Ta ble 4. Part B ( 6 -wee k i n O bese): Detaile d Sc he d ule (selecte d st u d y  d a y s) ........ 1 4 
Ta ble 5. Part C ( 6 - wee k i n T 2 D M): O verall Visit Sc he d ule a n d L ist of 
Pr oce d ures ( use wit h Ta ble 6 f or f ull details) ........................................... 1 5 
Ta ble 6. Part C ( 6 -wee k i n T 2 D M): Detaile d Sc he d ule (sel ec te d st u d y  da y s) ....... [ADDRESS_455832] u d y  Part A ........... 3 4 
Ta ble 1 0. P o p ulati o ns f or A nal y sis ................................ ........................................... 7 4 
Ta ble 1 1. Defi niti o n of Plas ma P K Para meters f or P F -0 8 7 0 8 1 5 3 2 .......................... 7 6 
Ta ble 1 2. Defi niti o n of Uri ne P K Para meters f or P F -0 8 7 0 8 1 5 3 2 ............................ 7 7 
Ta ble 1 4. Pr ot oc ol -Re q uire d Safet y L a b orat or y  Assess me nts ................................ .8 8 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 91. PROTOCOL SUMMARY
1.1. SynopsisNot Applicable.
1.2. Schema
This schema is provided for illustrative purposes only. 
TBD: To Be Determined; N: number of participants randomized; FU: follow-up
Dose levels represent PF-[ADDRESS_455833] titration schedules of less than, or more than, 14 days.
Based on emerging data, some cohorts (of Parts A, B, and/or C) may be run concurrently.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 101.3. Schedule of Activities (SoA)
The tables below provide an overview of the protoc ol visits and procedures that are tailored 
for specific cohorts as follows:
Part A : Table 1 andTable 2
Part B : Table 3 and Table 4
Part C :Table 5 and Table 6
Refer to the STUDY ASSESSMENTS AND PROCEDURES section of the protocol for 
detailed information on each procedure and asse ssment required for compliance with the 
protocol.
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA
tables, in order to conduct evaluations or assessm ents required to protect the well-being of 
the participant.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 1 T a b le 1.P art A ( 4 - w e e k i n T 2 D M) : O v er all Visit Sc h e d ul e a n d Lis t of Pr oc ed u r es ( u se wit h Table 2f or f u ll det a ils )
Scree n St u d y D a y ( a ll ac ti v iti es at 0 H[ pri or t o dosi n g] u n less ot her w ise s pecifie d ) F oll o w- u p E a rl y 
- 2 - 1 1 2 3 4 5- 
78 9- 
1 0 1 1 1 2- 
1 3 1 4 1 5 1 6 -
171 8 1 9- 
2 0 2 1 2 2 2 3- 
2 4 2 5 2 6- 
2 7 2 8 2 9 3 0 3 1 3 5- 
4 2 5 6 -
6 3 aTer mi n a ti o n
O ut patie nt vis it (after ≥8Hfa st) x x
Inf o rme d co nse nt x
De m o gr aphyandh e i g ht x
I n pa ti e nt st a y at CR U x                  x
Me dica l h ist or y xx
Revie w drug, alc ohol, tobac couse xx x
Re vi e w pri or /c o ncomitant t re at ment s xx x x x
A d verse eve n t m o nit ori n g x x                   x x x x 
Re vie w c o n trace pti o nus e/re q uire m ent xx xx x x
P h ysica lexa mi nati o n bxx x x x
B o d y w ei g h t x x x x x x x x
Bli n de d IPad mi nistr ati o ncxxxxxxxxxxxxxxxxxxxx
S u pi [INVESTIGATOR_050] 12-lea d E C G dx
See Ta ble 2 
See Ta ble 2 xex x x
See Ta ble 2 xex
See Ta ble 2 xex
See Ta ble 2 xxxx x
Supi [INVESTIGATOR_364934] g ns (bl o o d press ure and pulse r ate) fx xex x x xex xex xxxx x
Fasti n g fi n g er sti c k bl o o d gl uc o semeas ureme nt gx xxxxxxxx xxxx xxxx xxx
Sta n dar d izedmeals/ snac ks hx xxxxxxxx xxxx xxxx xxx
Bl o o dS a m pli n g f or: 
Safet y lab o ratoryte sts ix x x x xx x
F S Hj, HI V, He p Bs A g, He p B c A b , HC V A b x
P F -07 0 8 1 5 3 2 PK xex x xex xexe, k xkxkx
Uri n e S a m pli n g f o r: 
Uri ne dr u g test xx
Ur i n al y sis (andmicrosc o p y, asap pr o pri ate) x x x x xx x
a. T h is f oll o w -u p c o nt act ma y be c o n d ucte d as a p h o ne-call. 
b. Full p h ys ic al e x a m at ti mes i n dicate d ; l i m ite d e x a m f or p re vi o u sfi n di n gs ,ne w/ o p e n A E s, or i n v esti gat o r di sc reti on. 
c. D ose a d m i nistrati o n t o occ ur wit h bre a kf ast or mi xe d meal d a il y fr o m  D a y 1 t o Da y 2 8, i n cl usi ve; see Sect i o n 5. 3 a n d Secti o n 6 .
d. Si n gle 1 2 -l ea d EC G at Scree ni n g , fol lo w -u p a n d Earl y T er mi n ati o n (if a p pl ica ble ). Meas ure i n tri plic at e a t al l ot her ti mes i n di ca te d. 
e. Me as u re me nt/sa m ple at 0 H c orres p o n ds t o t he 2 4 H ti me p oi nt as detaile d i n Ta ble 2(ie, li ste d i n b ot h ta bles, b ut o nl y o ne sa m ple / m eas ure me nt s h o ul d be c ollec te d). 
f. Si n gle vit a lsi g ns at Scre e ni n g, foll o w- u p a n d Earl y T er m i n at i o n (i f ap plica bl e). Me as u re i n tri pli cat eat all ot her ti mes i n dicat ed. 
g. Fi n ge rs ti c k  gl uc ose via g l u c o m et er o n a d m issi o n t o C R U an d pr i o r t o br ea kf ast on all i n patie nt d a ys ; ma y be m ore fr e q u e nt at t h e dis cr eti o n of t he i n ves ti gat or. 
h. Me a ls t o b e pr o vi de d at a p pr o xi mat el y  0 H , 4 H , a n d 1 0 H rela ti ve to d osi n g ; s n ac ks t o be pr o v i de d . Re fe r t o Secti on 5. [ADDRESS_455834] me n o pa u sa l stat us o n ly. 
k. PKsa m ples o n Da y s 2 9, 3 0 a n d 3 1 t o b e c o lle cte d 2 4 H , 3 6 H , 48 H ,a n d 7 2 Haf te r the fi n al d ose o n Da y 2 8. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 2 T a ble 2. P ar t A ( 4- w e e k i n T 2 D M ): Det a ile d Sc he d ule (select e d st u d y d a ys) 
St u d y D a y H o urs Re l a ti ve t o D o si n g at [ADDRESS_455835] us Day 1 4 or Da y 2 1 kx x x x x x x
Tri p licate, su pi n e vi tal si g n s( bl oo d p re ss u re a n dp ul se ) Da y s-1,1,a n d 2 8 plus Day14 or Da y 21kx x x x x x x
Fasti n g fi n ge rstic k bl o o d gl uc ose measure me n tb, c All i n pat ie nt d ays x
Sta ndardiz edmeal/ snac kdAll i n patie nt da ys xex x x
Bli n de d invest iga ti o n al p roduct a d mi ni strati o n Dai ly: Da y  [ADDRESS_455836] in g f or :
-Saf et y lab o rat or y tes ts gDa y s-1,[ADDRESS_455837] us Da y 1 4 or Da y 21kx xx x xxxxxx x
Uri ne s a m pli ng f or: 
-Uri n a lysis a n d micr osc opy,as a p p ro pr ia te Da y s-1, 1 4 , 2 1 ,an d 2 8 x
-P K pre dose s pot uri n e( ur in e bla n k ) Day 1 o n l y x
-P F -0 7 0 8 1 5 3 2 P K mDa y 2 8 o nl y x             x   x x
a. Da y - 1, ti me of [ADDRESS_455838] i o n o n Da y 1. All o th e r da ys , 0 H p r oc e d u re s c o m p le te d p re -d o se .
b. T he 24 H sa mple / m eas ure m e n t i s to b e c o ll ect e d pri or t o d osi n g o n t he f o ll o wi n g m o r ni n g, as i n dica te d i n Ta b le 1.
c. Obtai n fa sti n g f i n gerstic k b l o o d g luc ose mea s u re m e nt via gl uc o meter b ef ore bre a kfa st o n al l d a ys w hi le i n p a ti e nt .
d. Sta n d ar d ize d meals/s n ac ks t o be p ro vi d e d o n al ld a ys w hil ei n pat ie n t; 
f. D osi n g t o o cc ur wit hbr ea kfast dai l y fr o m Da y 1 t o Da y 2 8 , i ncl u si ve .
g. See A p p e n d i x 2:Cli ni cal La b orat or y Te sts f or safet y la b tests t o b e c ollecte d at e ac h ti me p oi nt .
h. See Secti o n 5. [ADDRESS_455839] i n g i nter val f or i ncl us io n i n t he v ol u me c ol lecte d o v er t h at i nte r v al .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 3 T a ble 3. P art B ( 6 -wee k i n O bes e): O ve r a ll Visit Sc he d ule a n d Lis tof Pr o ce d ur es ( u se wit h T a ble 4f or f ull d et ails )
Pr ot oc ol Ac ti vit y Scr ee n St u d y D a y (all act i v it ies at 0 H [ pri or t o d os i n g] u nl ess ot he r w is e s pe ci fie d ) F oll o w- u p E a rl y 
- 3 a- 2 - 1 1 2 3- 7 8 9- 1 3 1 4 1 5- 2 1 2 2 2 3- 2 7 2 8 2 9 3 0 -3 5 363 7 - 4 0 4 1 4 2 4 3 4 4 4 5 4 9- 5 6 7 0 -7 7 bTer m 
O ut p a tie nt vi si t ( aft er ≥8Hfast) x x
Inf or me d co n sent x
De m o gr ap h y  a n d h e i g ht x
I n patie n t sta yat C R U ax                        x
Me di ca lhis tory x x
Re vie w d rug,alc o hol, t o bac c o use x x x
Revie w pr ior /c o nc o mi ta nt tr ea t me nts x x x x x
A d verse e ve nt m onit or i n g x x                         x x x x 
Re vie wcontra cepti o n use/re q uir e m e n t x x xx x x
P h ysic al e xa mi na ti o n cx x x x x
B o d ywei g ht x x x x x x x x x x
Bl inde d I P a d mi n istra ti o n dxxxxxxxxxxxxx x xx
S u pi [INVESTIGATOR_050] 1 2 -le a d EC G ex
See Ta ble 4 
See Ta ble 4 
See Table 4xfx x x
See Ta ble 4 xfx
See Ta ble 4 
See Ta ble 4 xfxxx x
Supin e vita l s i g ns ( b l o o d pres s u reandp u lse )gx xfx x x xfx xfxxx x
Fast i n gfi n gersti c k bl o o d gl uc o se hx xxxxxxxx xxx x xxx
Sta n dar dize d mea ls/snac ks ix xxxxxxxx xxx x xxx
Bl o o d S a m p li n g f or: 
-Safet y la b orator y tes ts jx x x x xx x
-F S H ,kHIV,Hep B sAg, He p Bc A b, H C V A b ,H b A 1c x
-PF-[ADDRESS_455840] i n gf or: 
-Uri ne dr u g t est x x
-Uri nal ysis (a n d mi cr oscop y , as a p p ro p ri at e) x x x x xx x
b. T his f oll o w -u p c o ntact ma y be c o n d ucte d a s a p h o ne call 
c. Full p h ys ic al e x a m at ti mes i n dicate d; li mite d e xa m f or p re vi o u sfi n di n gs, ne w/ o p e n A Es, or i n v esti gat or di screti o n. 
d. D ose a d m i nistrati o n t o occ ur wit h brea kf as t d ail y fr o mDa y 1 t o Da y 4 2 , incl usi ve ;se eTable 4,Secti o n 5. 3 a n d Secti o n 6 .
e. Si n g le 1 2-le a d E C Gat Scr ee ni n g, f oll o w- u p a n d Ea rl y Te r mi nati o n (i f a p pli ca ble). Meas u re i n t ri pli cate at all ot her t i mes i n d ic at ed. 
f. Me as u re m e nt/sa m ple at 0 H c orres p on ds t o t he 2 4 H ti me p oi nt as detaile d i n Ta ble 4(ie, li st e d i n b ot h ta bles, b ut o nl y o ne sa m ple / m eas ure me nt s h o ul d be c ollec te d ). 
g. Si n gl e vi t al si g ns at S cre e ni n g, foll o w -u p a n d Earl y T er mi n ati o n (if a p plica bl e). Me as u re i n t ri pl ica te at all ot her t ime s i n d icat e d. 
h. Fi n ger sti c k  gl uc os evia g l u c o met er o n a d missi o n t o C R U a n d pr i o r t o br ea k fas t o n all i n patie n t d a ys ; ma y be m o re fre q ue n t at t h e dis creti o n of t he i n ves ti gat or. 
i. Me a ls t o be pr o vi d e d a t a p p r o x i ma tel y 0 H, 4 H, a n d 10 H rela ti ve t o dosi n g ; s n ac k s m a y  b e pr o vi de d .  Refer t o Sect i o n 5. [ADDRESS_455841] e d 2 4 H , 3 6 H , 48 H ,a n d 7 2 H aft er t he fi nal P F- 0 7 0 8 1 5 3 2 d os e o n Da y 4 2. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI C CI 
C CI C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 4 T a ble 4.P a rt B ( 6 - w e e k i n O bes e) : Det aile d Sc he d ul e (se lecte d st u d y d a ys) 
St u d y D a y Ho ur s R el at i v e t o D o si ng at 0 H a
00. 2 5 0 . 5 11. 5 2 3 4 6 8 1 0 1 2 1 6 2 4 b
Tri p li cat e,supi n e1 2 -lea d ECG Days -1, 1, 2 8 ,a n d 4 2 x x x x x x x
Tri p lic at e, su pi [INVESTIGATOR_364935] g n (bl ood pres s u re a n d pulse rate ) Da ys-1, 1, [ADDRESS_455842] andar di ze d mea l/s n ac k dAll i n pat ie nt da y s x x x x
Blin d e d in v es tiga tional pr o duct a d m inistr at io n Dail y :Da y 1 t o 4 2 xe
Bl o o d s a m p li n g f o r: 
-Safe tylaborat or y testsgDa ys-1, 2 8 ,an d 4 2 xh
- P F- 0 7 0 8 1 5 3 2 P K Da ys 1 , 2 8 , a n d4 2 
Da y  4 1 0H o n l y f, k x x x x x x x x x x x 
-
Ur i ne s a m pli n g f or: 
-Ur i nal ysis a n d m icr osc o p y,asappr o pr iate Da y s-1,28,a n d [ADDRESS_455843] o n all i n patie nt da y s; ma y be m o re fre qu e nt at t h e discreti o n of t he i n ves ti gat or. 
d. St a n dar di ze d m ea ls /s nac ks t o b e pr o v i d e d o n all da y s w hi le i n p a ti e nt. R ef er t o Secti o n 5. [ADDRESS_455844] dail y fr o m  Da y 1 t o Da y 42, i ncl u si ve .
g. See A p pe n d i x 2 :Cli ni cal La b orat or y T est sf or saf et y l a b tes ts t o b e c ol lecte dat ea c h ti me p o i nt .
h. See Se cti on 5. [ADDRESS_455845] i n g r e q uir e m ents .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI 
C CI C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 5 Ta ble 5. P art C( 6- w ee k i n T 2 D M ): O v er all Vis it Sc h e d ule an d List of Pr oce d ure s( u se wit h T a ble 6for f ull det a ils) 
Pr ot oc ol Ac ti vit y Scree n St u d y D a y( all ac ti vit ies at 0 H[ p ri o r t o dosi n g] u nl ess o t h er w is e s pec ifi e d) F ol l o w U p E arl y 
- 2 - 1 1 2 3- 7 8 9- 1 3 1 4 1 5- 2 1 2 2 2 3- 2 7 2 8 2 9 3 0- 3 5 3 6 3 7 - 4 1 4 2 4 3 4 4 4 5 4 9- 5 6 7 0 - 7 7 aTe r m i n ati o n 
Outp a ti e n t visit (after ≥8-Hfast) x x
Inf o r me dco n se nt x
De m o g rap h ya n d h ei g ht x
I n pat ie nt s ta y at C R U                            x
Medical hist or y xx
Re v iewdrug,alcoh o l, tob a cc o us e xx x
Re vie w p ri or /c o nc o mi ta nt tre at m e n ts xx x x x
A d ve rs e e ve nt m o nit ori n g x                           x x x x 
Re vie w c o nt race pti o n use /re q uir e me nt x x x x x
P h y sica l exa m in a ti o nbxx x x x
B o d y wei g ht x x x x x x x x x x
Blinded I P admi ni str ati o n cxxxxxxxxxxxxx x x
S u pi [INVESTIGATOR_050] 1 2-lea d E C Gdx
See  Ta ble 6 
See  Ta ble 6 xex x x
See  Ta ble 6 xex
See  Ta ble 6 xexx x x
Su pi [INVESTIGATOR_364934] g ns ( bl o o d press ure and p ul se) fx xex x x xex xexx x x
Fast i n g fi n gers tic kbl o o d gl ucose meas ur e me nt gx xxxxxxxx xxx x xxx
Sta n dar dize d meals/ s n ac k shx xxxxxxxx xxx x xxx
Bl o o d S am p li n g f or :
-Saf et y la b ora t o r y te sts ix x x x x x x
-F S H ,jHI V, He p B s A g ,He p Bc A b, H C VAb x
-P F - 0 7 0 8 1 5 3 2 P K xex x x x ex xkxkxk x
Uri n eS a m pli n g f or: 
-Urine dr ugtest xx
-Uri n alysis (an d mic r o sc o p y , as a p pr o p riate ) x x x x x x x
a. T his f oll o w -u p c o ntact ma y be c o n d ucte d as a p h o ne ca ll 
b. F ull p h ysic al e x a m at ti mes i n dicate d ; li mite d e xa m f or pre vi o us fi n di n gs, ne w/ o pe n A Es, or i n vesti gat or d is cre ti o n. 
c. D ose a d m i nis trat io n t o o cc ur wit h brea k fast d a il y o n Da ys 1 t o 4 2 , i n c l u si ve , se eSecti o n 5. 3 an d Secti o n 6 .
d. Si n gle 1 2 -lea d E C G at S cr ee ni n g , fol l o w -u p a n d Ea rl y Ter m i nat io n (i f a p pl ica ble) . Meas ure i n tri p licate at all o ther ti me s i n dic at ed. 
e. Me as u re me nt/sa m ple at 0 H c orres p o n ds t o t he 2 4 H ti me p oi nt as detaile d i n Ta ble 6(ie, li ste d i n b ot h ta bles , b ut o nl y o ne sa m ple / m eas ure me nt s h o ul d be c ollec te d). 
f. Si n gle vit al si g ns at Sc re e ni ng, f o ll o w- u p an d Earl y Ter mi na ti o n (i fa p pl ica b le ). Me as ure in tri plicat eat all ot her ti mes i n dicate d. 
g. Fi n g er sti c k  gl uc ose via g l u c o m et er o n a d m issi o n t o C R U a n d pr i o r t o br ea k fast on all i n patie nt da ys ; ma y b e m ore fre q ue n t at t h e discreti o n of t he i n ve st i gat or. .
h. Me a ls t o b epr o vi d e d at a p pr o x i mate ly 0 H, 4 H, a n d 1 0 H rela ti ve t o d os i n g; s n ac ks ma y  b e pr o v ide d . Refer t o Secti o n 5. [ADDRESS_455846] es o n Da y 4 3, 4 4 ,a n d 4 5 ar e t o b e col le cte d 2 4 H, 3 6 H , 4 8 H ,a n d7 2 H aft er t h e fi na lP F -0 7 0 8 1 5 3 2 d o se o n Da y 4 2. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 6 Ta ble 6. P ar t C( 6- wee k i n T 2 D M) : D e t a ile d Sc he dule ( sel ecte d s t u d y d a ys )
St u d y D a y H o urs Rel ati v e to D os i n g a t 0 H a
00. 2 50. 5 1 1. 5 2 3 4 6 8 1 0 1 2 1 6 2 4 b
Tri p licat e, s u pi [INVESTIGATOR_050] 1 2 -le a d ECG Da y s -1, 1, 2 8 ,and 4 2 x x x x x x x
Triplica te, su pi n e vital si g n (bl o o d p ress ur e a ndpuls e) Days -1, 1, [ADDRESS_455847] ing fi n gerstic k bl o o d gl ucose me as ure me nt b, c All i n patie ntda ys x
Sta n dar dize dme al/ s na c k dal linpatie nt da ys xex x x
Bli n de d investi ga ti o n al pr o d uct a d mi nist rati o n Dail y: Da y1 t o Da y [ADDRESS_455848] ing for:
-Safet y la b orat or y test sgDa y s -1, 2 8 ,a n d 4 2 xh
-H b A1c, TS H Da ys-1,28,a n d 42 x
-PF-07 0 8 1 5 3 2 P K Da y s 1, 2 8 ,a n d 4 2 x xx x xxxxxx x
-Urine sa m pli ngf or :
-Uri nalysis andmicr osc opy,as appropriat e Da ys -1,2 8 ,a n d 4 2 x
-PK pr e d ose s p otur i n e( uri n e bla n k ) Da y 1o nl y x
- P F- 0 7 0 8 1 5 3 2 P K Da y 4 2 o n l y kx             x   x x
a. O n Da y -1, ti me of  [ADDRESS_455849] on all i n pati e nt da ys ; ma y be m or efre q u e nt at t h e discreti o n of t he i n ves ti gat or. 
d. St a n dar d iz ed m ea ls/s n a c k s t o b e pr o v i d e d on a ll d a ys w hi le i n pati e n t; 
f. D o si n g t o occ ur wit h bre a kf as t dail y fr o m Da y 1 t o da y 4 2 ,i n cl u si ve .
g. See A p pe n di x 2:Cli ni cal La b orat or y Te sts f or sa fe t y la b t est s t obe c ollecte d at ea c h ti me p oi nt .
h. See Secti o n 5. [ADDRESS_455850] i n g i nter val f or i n cl usi o n i n t he v ol u me c ollecte d o ve r t hat i nter val . 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 7 2. I N T R O D U CTI O N 
Gl u ca g o n -li ke pe pt i de- 1 ( G L P- 1) is a ne ur o en d oc ri ne h o r m o ne t h at is p re d o mi na n tl y
re lea se d fr o m t h e smal l i n tes ti ne i n res p o ns e to f o o d i n ta ke .[ADDRESS_455851] ivati o n of t he G L P- 1 
rece pt or ( G L P -1 R) st im u lates i n s ul i n release ,i n hi b its gl uca g o n secr eti o n i n a gl u c o se -
de pe n de nt ma nner ,a n d d ela y s ga st ri c e m pt yi n g .2,3I n a d di ti o n, G L P- [ADDRESS_455852] t o die t a n d e x er ci se t o i m pr o ve gl yce mi c c o nt r ol i n 
a d ult s wi t h t y pe 2 dia bet es melli t us ( T 2 D M). 
2. 1. St u d y R a ti o n ale 
T he p ur p ose of t h is st u d y  is t o e val uate t h e s afet y, tol era bilit y,a n d p h a r m ac o ki netic s ( P K )of 
m ult i p le oral d ose s of P F -[ADDRESS_455853] a p pr o xi mate l y 4 2 5 m illi o n a d ult s( 8 . 8 % of pe o pl ea ge d 
2 0- 7 9 ye ars) w o rl d - w i d e. 5,6T h ei nc re ase i n t h egl o bal pre val e nc eof T [ADDRESS_455854] a nce r e s u lt i n t he ne e d f o r m ore i ns uli n o ve r ti me ,
eve n t ual l y res ul ti n g i npro gr ess i ve pa n c rea tic -cell fail ur e.8Patie nt s wi t h p o orl y c o ntr ol le d 
T2 D M ha v e a ni nc re ase d ris k o f d e ve lo pi n g co m p lic ati o ns ass ocia te d wi t h b o t h 
mic r o va sc ul ar a n dmacr o v as c ula r dis ease , i n cl u di n g ne p hr o pat hy, ne u r o pat h y , r et i n opat h y, 
car di o vas c ular dis ea se a n d str o ke, a n d a re at [ADDRESS_455855] o r y gl y ce mic c o n tr ol f or s o me pa tie nt s, t he re re m ai n ma n y  
pati ents w h o d o n o t ac hie v e t ar get gl yc at e d he m o gl o bi n ( H b A 1c) le ve ls, s u gge st i n g a nee d
f or a d diti o na l t her a pe utic o pt i o ns. 
Bas e d o n t h e cl i n ical hist or yof i njec ta bl e G L P- [ADDRESS_455856] ed t o i m p r o ve gl u c ose c o ntr ol a n d r e d uc e Hb A 1c l e vel s i n pati e n ts w it h T 2 D M, w hil e 
de cr easi n g f o o d i nt a k ea n d b o d y w ei g h t a n d a v oi di n gt h es u bc u ta n eo us i nj ec ti o n r e q uire d b y 
the ma jori ty of c u rr e nt ly a vai la b le pe pt i d ic G L P- 1 R a g o n ists .  
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 8  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455857] he o nl y  p ha r m ac o l o gi ca ll y rel e va nt 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 2 0 n o ncli nica ls pe cies (P F -[ADDRESS_455858] ivat es t h e G L P- 1 r ec e pt or ), t h er ef or e ra t was use d t o 
c haract eri ze off -tar get a cti vit y o f t he m o lec ule .
I n t he 8 -we e k or al ga v age t o xi ci t y s t u d y c o n d u cte d i n c yn o m ol g us m o n ke y at 2 0, 6 0, a n d 
1 0 0 mg/ kg/ da y, n o a d verse effec ts w ere d etec te d. 
 
A 6- we e k or al ga va ge t o xi ci ty st u d y wa s c o n d u ct edi n Wist ar Ha n rats at P F- 0 7 0 8 1 5 3 2 d oses 
of 3 0, 1 0 0, a n d 3 0 0 m g/ k g / da y.    
 
 
 
 
The NO A E L i nt h e p i v ot al [ADDRESS_455859] u d y i n m o n ke y swas 1 0 0 m g/ k g/ da y  
 
 a nd t h e N O A E L in t he pi v otal [ADDRESS_455860] u d y i n r a ts was 1 0 0 m g/ k g /d a y 
P F -[ADDRESS_455861] u d y .Ba se d o n t he m ol ar e x tincti o n c oefficie nt f or PF- 0 7 0 8 1 5 3 2, t he 
p h ot ot o xi c ris k was e v al u at e d i n t he 3T 3 Ne utr a l Re d as sa y  des cri b e d i n I n ter nat i o na l 
C o u ncil f or H ar m o nis ati o n ( I C H) S [ADDRESS_455862] e ms d i d n ot i de nti f y a n y ef fec ts at d os es u p t o 
3 0 0 m g/ k g i n ra ts .  
 
F u rt he r d etails of t h e n o n cli nical s afet y pr o gra m ar e pr o vi de di n t he c ur re nt I B.
2. 2. 4. C li ni c a l E x pe rie nc e w it hP F - [ADDRESS_455863] b o 
s u bstit uti o n desi g n i n 2 i nt erlea vi n g c o h orts of healt h y  a d ul t partici pa nts.  T he f oll o wi n g is a 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 2 1 bli n de d i nteri m draf t s u m mar y  of t he e mer gi n g cli nical safet y a n d P K d ata a vaila ble t o date 
( 7 t h Ja n uar y  2 0 2 0) . All data pr o vi de d bel o w s h o ul d be c o nsi dere d preli mi nar y  a n d s u bject t o 
u p dat e o n fi nal re p ort i n g of t his st u d y ’s res ults. 
Si xtee n ( 1 6) partici pa nts ha ve bee n ra n d o mise d t o partici pate i n C [ADDRESS_455864], vit al si g n sa n d E C G . 
T here ha ve be e n n o deat h s, n o s us pecte d u ne x pecte d seri o us a d verse reacti o ns ( S U S A Rs), 
a n d n o a d verse e ve nts ( A Es) of se vere i nte nsit y  re p or te d .  T he m ost fre q ue ntl y  re p orte d A Es 
ha ve bee n i n t he gastr oi ntest i nal s y ste m, c o nsi ste nt wit h mar kete d G L P 1 -R a g o nists. 
 
 
 
 
 
 
 
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 2 2  
 
 
 
 
 
 
2. 3. Be ne fit/ Ris k Assess m e nt 
T h isst ud y is de si g n e d pri ma ri l y t o g e nerate safet y, tolera bil it y , a n d P K dat afr o m a d ul t 
par ti ci pa nts wi t h T [ADDRESS_455865] rat i o n ha ve bee n ide nt ifi e d ;da ta gat here d d uri n g n o n cli n ic al s t u di es wit h 
P F- [ADDRESS_455866] ere d onl y af te rl o we r d oses h a ve bee nf o u n d t o be well t olera te d wit h a n acce p ta ble 
safe t y pr ofi le (se e Secti o n 4. [ADDRESS_455867] e d d o se le v els , a n d Se cti o n 6. 6. 1 for d os e escalati o n a n d s t o p pi n g rul es). I n a d diti o n, 
this st u d y i n cl u de s s ta n dar d, i nte nsi ve ,i n pat ie nt m o nit or i n gof t he pa rtici pa n ts f oll owi n g 
a d mi n istrati o n of m ult i pl e, oral d oses of t h e i n vesti gati o na l pr o d uc t ( I P). Cli nic al sa fe t y 
la b ora t or y test s, t h or o u g hassess me nt s of vita lsi g ns a n d elect r o car di o gra ms ( EC G s) , p h y sic al 
e xa mi nati o ns a n d a d ver se e ve nt ( A E) m o n it o ri n g w ill pr o vi de ess e n ti al da ta t o e val uat e t he 
safe t y  a n d t olera bil it y  of P F- 0 7 0 8 1 5 3 2. 
T he p ot e ntial l y  i m p or ta nt ris k sof mar kete d i njecta ble G L P- 1 R a g o nis ts , b as e d on t he 
appr o ve d la b el i n g ( U nite d Stat es Pac k a ge I ns ert a n d Eur o pea n U n i o n ( E U )S u m mar y of 
Pr o d uct C h ara cter ist ic s) are s u m marize d i n t he c urre nt P F -[ADDRESS_455868] u dies wi t h P F -0 7 0 8 1 5 3 2 , see Secti o n 5 .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 23More detailed information a bout the known and expected benefits and risks and reasonably
expected adverse events of PF-07081532 may be found in the IB, which is the SRSD for this study.
Considering all available clinical and nonclinical data, the benefit-risk profile of
PF-07081532 supports continued clinical development.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 2 4 3. O B J E C TI V E S A N D E N D P OI N T S 
Pr i m ar y O b je cti v e: Pri m a r y E n d p oi nts : 
T o e v al u at e t h e safet y a n d t o ler a b ili t y o f 
esc alat i n g, m ulti ple d oses of 
P F- [ADDRESS_455869] e d, 
t o n o n- dia be tic o be se p a rtici p a n ts .Asses sme nt of A E s, sa fet y la b ora t o r y  
tes ts , vital si g ns a n d [ADDRESS_455870] i ve s: Sec o n d ar y E n d p o i nt s: 
T o c h arac te ri ze plas m a P K of 
P F - 0 7 0 8 1 5 3 2 f oll o wi n g m ulti p le d os es 
a d m i n is ter e d ora ll y toa d ult part ici pa nt s
wit h T 2 D M i na de q ua tel yc o ntr olle d o n 
metf or m i n a n d, if c o n d u cte d, to 
n o n- dia bet ic o b es e partici p a nt s. P F - 0 7 0 8 1 5 3 2 pla s m aP K par amet ers *
A U C 2 4 , C ma x ,Tma x , t ½o n D a y 1a n d 
f o ll o wi n g m u lti ple ,oral d ose 
a d mi nistr at io n, as data pe r m it. 
T o c haract eri ze t he uri n e P K of 
P F- [ADDRESS_455871] ere d orall y t o a d ul t partici pa n ts
wit h T 2 D Mi n a de q uate l y c o ntr oll e d o n 
me tf or mi n .Uri n e P K pa r a met ers *f o r 
P F - 0 7 0 8 1 5 3 2, a s dat aper mit : Ae2 4 , 
Ae 2 4 %, a n d C Lr f oll o wi n g m ulti p le, 
ora ld os e a d m i n istr at i o n, as data 
per m it . 
 
 
 
 
 
  
 
 
  0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 2 5   
 
 
 
  
 
 
  
 
  
 
*Par a meter s a re defi ne d i n T a ble 1 1 ,Ta ble 1 2 ,Ta ble 1 3 a n d/ or A p pe n di x 8: Ab bre viati o ns. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 2 6 4. S T U D YD E S I G N 
4. 1. O v er al lDesi g n 
T h is is ara n d o mize d, d o u bl e- b li n d ( i n v esti ga t o r- a n d pa rti ci pa nt -bli n d ),s p o ns or- o pe n , 
plac ebo-c o n tr o lle d, m ulti ple ora l d ose- e scalati ng st u d y of P F - 0 7 0 8 1 5 3 2. 
There ma y b e 2 par ti ci p a nt p o p ul at i o ns e nr oll e d i n t hi s stu d y : pa rt ic i p a nts e nr oll i n g wit h 
T 2 D M (as i n d icat e d b y  H b A 1 C le ve l a t s cree ni n g, s ee Secti o n 5 )a n d n o n- d ia b et ic o bes e 
partici p a n ts(as i n dic ate d b y  B MI a t sc re e n i n g, se e Secti o n 5 ). T he st u d y  w ill be c o n d ucte d
i n u p t o 3par ts , p ort io ns o f w hic h ( se e Secti o n 4. 3 )ma y  be co n d ucte d c o n c u rre n tl y. 
Part A: a d ult pa rt ici pa nts w it h T 2 D M i n ade q u at el yc o ntr oll e d o n m etf or m inw h owi ll 
re cei ve P F - 0 7 0 8 1 5 3 2 or p la ce b odail yf o r2 8 d a y s. U p t o 5 s uc h c o h o rt swi ll be e nr o lle d, 
wi t h ap pr o xi m at el y 1 0 p a rti ci pa nts (8 P F- 0 7 0 8 1 5 3 2: 2 pla ce b o) per c o h or t.  F or i n di vi d ual 
pa rtici pa nts i n P art A , t he durat i o n of t h e s tu d y fr o m t he Scree ni n g visi t t o t he o n -site 
fol l o w -u p vis it will b e a p p r o xi mate l y  1 0 wee k s o f w hic hap pr o x i matel y  3 3 da y s will be 
i n pati e nt at t he C R U .
P a rt B( o pti on a l): o bes e ( n on d ia bet ic) a d ult partici pa nt s w h owill rec ei ve P F - [ADDRESS_455872] u d y pa rt f or w hic h u p t o 2 co h ort s ma y b e 
e nr o lle d wi tha p pr o xi matel y 1 5 o bese par tici pa nt s (12P F - 0 7 0 8 1 5 3 2: 3 pla ce b o) p er c o h ort. 
 
F or in di vi d ual p ar ti ci pa nt si n Part B, t he d ura ti o n of t h e st u d yfr o m t he 
Scree ni n g v isi t t o t he o n -sit e f o ll o w- u p visit wi ll be appr o xi matel y 1 2wee ks of w hic h 
ap pr o xi ma tel y  4 8 d a y s will be i n patie nt at t he C R U .
Part C( o pt io n a l) : a d u lt pa rt ic i p a nts wit h T [ADDRESS_455873] ac e b o dai ly f or 4 2 da y s. U p t o 2c o h ort sof 1 0 p art ic i pa n ts 
( 8 P F- 0 7 0 8 1 5 3 2: 2 p lace b o pe r c o hort ) ma y be e n r o ll e d if j u d ge d nec ess ar yt o meet t he st u d y 
o bjecti ve s. For i n di vi d ual par ti ci pa n ts i n Pa rt C , t he d ur ati o n of t he st u d y fr o m t he Scree n i n g 
visi t t o t he o n -site foll o w - u p v isi t w il l b e a p pr o xi mat el y [ADDRESS_455874] u d y  parts, partici pa nts will i nitiall y  ret ur n t o t he cli nical resear c h u nit ( C R U) [ADDRESS_455875] 
a d mi nistrati o n of I P ; t hi s c o ntact m a y  be d o ne via a p h o n e call .
T he st u d y  will be c o n d ucte d i n t h eU S.  W h ere m o re t h a n [ADDRESS_455876] u d y m a y be re pla ce d, at t he d iscreti o n of t he 
pri nci p al i n vesti g at or ( PI) a n d s p o ns o r. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455877] u d y  is to e val uate th e safet y, t o lera bi lit y ,a n d P K of m ulti ple 
es calati n g oral d os es o f PF- 0 7 0 8 1 5 32 i n a d ult pa rti ci pa nts wit h T 2 D M.  
4. 2. 1. P o p ul ati o n (s )
T he p o p ula ti o n pla n ne d f ort his st u d y w il l be male a n d fe ma le a d ul t pa rtic i p ants . F e ma le 
parti ci p a n ts wi ll be w o me n of n o n -c h il d be ari ng p o te n tia l ( W O N C B P), si nce at t h e pr ese nt 
ti m e e m br y o fe tal de v el o p m ent t o x ic ity st u di es wit h P F - 0 7 0 8 1 5 3 2 ha ve n o t bee n c o n d ucte d. 
I n male pa rti ci pa nts a p p ro pri at e meas ur es ar e e x pec te d t o b e foll o we d t o li mit p ote ntia l 
tra n sfer of P F- 0 7 0 8 1 5 3 2 i n s e m en t o par t ne rs (s ee Ap pe n d i x 4). 
Pa rt ici pa n ts e n r o ll e d in t his st u d y will be a d ult s w it h ina de q uate l y  c o ntr o lle d T2 D M (as 
i n di cate db y H b A 1c at sc re e n i n g )o n metf or mi n m o n ot hera p y , w h ic h is c o ns i de re dfirst-l i n e
t h era p y for g l y ce m ic co ntr ol acc or d i n g t o c u rr e n ttrea tme nt g ui d el ines. [ADDRESS_455878] 
5 0 0 m g/ da y  f or a t leas t [ADDRESS_455879] u d y par tici pati o n (i e, f o ll o w -u p 
visit ). A vai la b le i n vitr o da ta s u g ges tt ha t P F -[ADDRESS_455880] t he PK of 
metf o r m i n via i n h i b iti o n of or ga n ic cati o n t ra ns p ort er ( O C T ) 2, a n d t h e ris k of a cl i n ic al 
i nter acti o n is dee me d ne g li gi ble .
Ther eis prece de nt f or a G L P- [ADDRESS_455881] be i n g in d icate d f or o be sit y ( Sa xe n da®, l ira gl uti de 
3 m g) .  P F- [ADDRESS_455882] u di es (Secti o n 2. 2. 3 ). A ll p ar tici p a nt swill 
be co nfi ne d t o t he cl i nical r esearc h u nit ( C R U ) d uri n g d osi n g peri o ds as d etai le d i n t he 
Sc h e d u le of Acti viti es .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI 
P F -[ADDRESS_455883] u d y .  T his ma y n o t be necess ar y f or a ll c o h orts ( see Secti o n 4. 3. 5 ). 
M ul ti ple es cala ti n g dail y  oral d oses of P F - [ADDRESS_455884] u d y  Part C.  
I n Part Bof t his s tud y ,if c o n d ucte d, n o n- d ia beti c o bese partici p a nts ma y be enr o lle df or 
4 2 d a y sof d osi n g.   T he d u ra ti o n of d os e a d mi n istrati o n i n t his c o h o rt is bas e d o n a n tic i p ate d 
ti me n ee de d t o t it rat et o h i g her d oses of P F- 0 7 0 8 1 5 3 2 t ha t ma y b e nee de d t o tr eat o besit y   
D o si n g of i n ves ti gat i o nal p r o d uc t (I P )is pla n n e d t o o cc ur i n t he f e d sta te ,ie, wit h brea kf ast .  
W hile ,bas ed o n p h y si c oc he mic al p ro per ties a n di n sil ic o pre di cti o ns, f o o d is n o te x p ec te d t o 
ha ve a si gnifi ca nt i m pact onP F - [ADDRESS_455885] i ves (e g, to as s e ss t ole ra bi li t y  o r e x p o s ure ), t h e t imi n g of me als or s n ac ks relati v e t o
st u d y trea t me nt a d mi ni str ati o n ma y be a ltere dd u ri n g an y  o ft he s t u d y c o h ort s; s h o ul d t his be 
ne ces sar y , details will be p r o v i d e d t o i n ves ti ga t o rs i n wr it in g. 
4. 2. 3. St u d y Bl i n di n g 
T o per mit a n u n bi as e d asse ss me nt of s afet yt h ep a rtic i pa nt s’ tr ea t me nt as si gn m e n ts (acti ve 
tr eat m e nt v ers u splace b o) wi ll be bl i n dt o b ot h si te sta ff (e x ce pt t h o se i n v o l ve d i n pre pa rati o n
of d os es ) a s we ll a s t he st u d y pa rti ci p a nts .  H o w ever, t o p er mi t real -ti m ere v ie w oft h e s afet y
a n d P K dat a, ali mit e d n u m ber o f s p o ns or st u d y te am m e m bers will be u n bl i n d e d (se e 
Sect i o n9. 5 ). 
4. 2. 4. E n d p oi nt s
4. 2. 4. 1. S a fet y 
Gi v en t hat t he c urre nt st u d y  is t he first t o a d m i nis ter re p eat e d d o s e s of PF- 0 7 0 8 1 5 3 2 t o 
huma ns, a n es calat i n g d es i g n wit h ca re f u l o n- g o i n g re vie w of safet ya n d P K o fP F - 0 7 0 8 1 5 3 2 
ispla n ne d .D o ses a n d d ose titra ti o n sc h e mes (if u s e d) i n t he esc alati o n se q u e nce ma y  be 
m o difie dor re peate das g ui d e d b y e me r g i n g sa f e t y , t o le ra bili t y ,a n d P K da t a a n d will be 
pr o v i d ed t o i n vest i gat o rs i n w ri ti n g p ri or t o i nit iati o n of d os i n g. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -[ADDRESS_455886] s, t h or oug h as s e ss me nt s of v ita l s i g ns a n d 1 2- l e a d E C Gs, 
p h y sical e x ami na ti o ns, a n d AEm o nit ori ng will pr o vi de e ss entia l data t o e v a l ua te t he saf et y 
a n d t o lera bi li ty of P F - 0 7 0 8 1 5 3 2. 
 
  
W h ile G L P-1 R a g o nists t y pi[INVESTIGATOR_1306] y  are n o t a ss o c ia te d w it h h y p o gl yc e m ia unle ss
c o -a d m i nis tere d wit h a nti- di a bet ic a g e n ts t h at ca n ca use h y p o g l y ce mi a(s uc h as i ns uli n or 
s ulf o n yl urea s), bl o o d g l uc ose c o n ce ntra ti ons w ill be m o nit o re d thr o u g h out the st u d y vi aa 
gl u c o me ter at leas t o nce dail y  ( pre -brea kfast ), an d ca ref u l m o nit o ri n g of s y mpt o ma tic 
h y p o g l y ce mic A Es wi ll be pe rf or me d. 
Baseli ne ( Da y - 1) a sse ss me nt s wit h t i me -matc he d pr o ce d ur es will per mit wit hi n partici pa nt 
c o m p aris o ns, as a p pr o p ri at e. I n a d dit i o n, place b o- a dj u ste d ( be t wee n s u bject) c o m pari s o ns of 
dose -res p o n s e wil l a ls o be c o n d uc te d. 
I n aneff ort t o re d u ce varia bi lit y  a n d b etter qu a nti f y a n y p ot e n tial cha n ges i n hea rt r a te a n d
bl o o d press ure ( B P) d uri n g t h est ud y, all meas ure me nts of E C G a n d vital si g ns ( p ulse a n d 
B P )will be c ol lec t e di n t ri p lica te (e xc e pt as n ote d in t h e Sc h e d ule of Acti vit ies )a n d the 
mea n val ues wi ll be u se d f or a nal ys is at ea c h ti me p o i nt .  
4. 2. 4. 2. C h ar act eri z at i o nof P F - 0 7 0 8 1 5 3 2 P h ar m a c o k i netic s
As is t y pi[INVESTIGATOR_19529] l f orm ulti p le asc en di n g d ose ( M A D )st u di es wi th i n vesti g at i o nal a ge nts, t his 
st u d y  will i nc lude sa m pli ng t o e xa mi ne the D a y  [ADDRESS_455887] u g e xcr ete d via r e na lel i m i na ti o n.  
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI C CI 
P F -[ADDRESS_455888] u d y  C 3 9 9 1 0 0 1.  0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455889] u d y , a star ti n g d os e of 1 0 m g Q D P F - 0 7 0 8 1 5 3 2 is pla n ne d .   
 
 
 
 
D ue t op ote ntia l tolerati o n of gastr oi n te sti nal a d vers e e ve nts t hat ha ve bee n s h o w n t o o cc ur 
wit h G L P- 1 a g o nists, d o s e s of P F -0 7 0 8 1 5 3 2 wi thi n a c o h ort ma y be titrate d fr o m a l o w d os e 
u p t o t he tar ge t d ose t hat is e x pe cte d t o be o b ta ine d b y t he c o nc l usi o n of t he dosi n g p eri o d. 
Be y o n d t h estar ti n gd ose. t he pla n ne d dose esc alati o n pr oce d ur e wil l be dic t a te d b y t he r ules 
s u m marize d i n Secti o n 6. 6. 1 a n d is ai m e d t o oc c ur i n itiall y in i ncre me ntal i n cre as es of 
a p pr o xi mate l y  ≤ ½- l o g ( i e , a p pr o xi matel y  3. 3 -f ol d) base d o n pre dicte d e x p o s ure. Thes e 
incre me nts m a y  be a dj uste d ba se d o n e mer g i n g safet y t olera b ilit y  a n d P K data. 
D ose -escalati o n is e n visi o n e d t o pr ocee d u p t o t he hi g h est d ose dee me d t o be w el l t olerate d 
wit h a n ac ce p ta ble saf et y pr ofile, ac hie ve me nt of plas ma e x p os ures e q u i v ale nt t o t h e P K
st o p pi n g li mits (see Se cti o n 6. 6. 1 ). 
4. 3. 2. Dose Selecti o n-- P art B
Pa rt B i n o be se n o n- dia betic par ti ci pa nts is o pti o n al.  D o si n g i n Part Bm a y oc c ur afte rdata 
fr o m at lea st 2c o h orts i n Pa rt Aare re vie w e d b y t h est u d y tea m (D a y 2 8 s a fet y, D a y 14 or 
2 1 P K) . Part B o f t he st u d y e nr olls a differe n t p o p ul ati o n t h at ma y ha ve a dif fe re nt 
t ol era bil it y p r of il e re lat i v e t o T 2 D M a n d al l o ws f o r a l o n ger t it ra ti o n peri o d t ha n Part A ( u p
t o 6wee ks) .  T hi sm a y  a ff or dt he o p p o rt u ni tyt o ac hi e ve hi g her t ar get doses i n P art B.  T h e
ta rget d o se i n Part B ( C o h ort 1) w il lbe n o gr ea ter t ha n a p pr o xi matel y  3. 3-f o l d hi g her t ha n a
dose pr e v i o usl y teste d i n t he st u d yt ha t was d e e m e d t o be a de q uatel y t olerate d a n d h as 
e x p os ur es pr oje cte d t o be less t ha nt he P K st o p pi n g li m it s. D o ses i n Part Bar e e x pe cte d t o 
be titrat e d t o t he tar get d ose o ve rt he 4 2 d a y s o f t he tre at m e nt peri o d .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -[ADDRESS_455890] u d y t ea m (D a y 2 8 s a fe ty, Da y 1 4 o r 2 1 P K ).  Part Cof t he st u d y  
all o w sf or a l o n ge r ti tra ti o n pe ri o d ( u p t o 6 we e k s) a n d t h ere f ore ma y  all o w f or atta ini n g 
hi g her ta r get d ose s i n Part C, re lati ve t o Part A.  T he tar ge t d os e i n Part C ( C o h ort 1) will be 
n o gre ate r t ha n a p pr o xi mate l y  3. 3-f o l d hi g h er t ha n ad ose pre v i o usl y teste d i n t he st u d y that 
was dee me d to b e a de q u ate lyt olera te d a n d h a s e x p os ures pr o ject e d t o be le ss t ha n t he P K 
st o p pi n g li mits.   D oses in Pa rt C a re e x pect e d t o be tit rate d t o t he tar g et dose o ver t he [ADDRESS_455891] u d y ( 1 0- 3 0 0 m g Q D , b ut wit h t he p o te nt ial t o escalate u p 
t o 1 0 0 0 m g Q D de p e n di n g u p o n o b ser vati o ns a t l o w er d os es )was c h ose n i n or der t o 
a p p r o pri at el y b rac ket t he pr oj ecte d ef fi ca ci o us d os e t o c o ver t he p ote ntial i m p act o f
u nce rta i n tyi n pr o jec ti o n of e ff ic ac i o us c o n c e n tr ati o n or of u na ntici pate d f act ors o n d r u g 
e x p os ure, w hil eacc o m m o dat i n g f ea si b ili t y  c o ns i derat i o ns . 
  
Pr e di cte d e x p os ur e le v els a n d saf et yma rgi n s f or ara n g e of anti ci pat e d d oses f o r t hi s st u d y  
are pr o v i de d inTa b le 8 b e l o w.  All e x p os ure -bas e d sa fe t y  ma r gi ns we recal c ul ate d usi n g 
u n b o u n d c o n ce n tr ati o ns.  T his ta ble gi ves an o ver vi e w of t h e p ote n tial d o se le ve ls ; h o we v er ,
d oses ma y  be a dj u ste d as l o n g as t he t he pr ojec te d i nc re me nt of C ma x a n d A U C [ADDRESS_455892] u d y; detai ls are pr o vi de d i n 
Se cti o n 4. 3. 5 .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455893] u d y P art A: it is e x pecte d t h at t h ese co h orts will re q uir e u p t o [ADDRESS_455894] u d y P art sBa n d C : t he titrati o n sc he me t o be use d i n P art sB a n d C will be det er mi ne d 
base d o n da ta e m er gi n g fr o m Pa rt A a n d ma y  or m a y n o t incl u de a sta bl e d o si n g peri o d . T he 
t ot al d urati o n of d os ea d mi nistra ti o n t o a n y  gi ve n parti ci pa nt i n Part s B or C will n ot e xc ee d 
4 2 da y s. 
D uri n g th e titrati o n peri o d ,if a pa rtici pa nt d oe s n o t t o lerate t itrati o n t ot he ne xt d os e le v el, as 
dete r mi ne d b y t h e i n vesti g at or a n d wit h n otificati o n t o t he sp o ns or, t he partici pa n t ma y be 
re verte d t o t he pr e vi o usl y t olerat e d d ose le v el, a n d d ose titrati o n t o t h e ne x t hi g h er d os e m a y 
be dela y e d b y 1 t o 2 d a y s or l o n ger, as n ee de d. F oll o wi n g d o w n -titrati o n, 2se p arat e atte m pts 
at u p -titrati o n t o t he ne xt d ose le vel are per mitte d, per i n vesti gat or discreti o n .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 3 4 If , per i n vesti g at or ass ess me nt, u na cc e pta ble i nt ol er a n ce (e g, se v ere v o miti ng) occ urs s h ort ly 
f ol l o wi n g d os e a d mi nistr ati o n, t he d o se will not be re - a d mi n ister e d a nd t h e par tici pa nt m a y 
res u me d osi n gat t he c urre nt d ose le vel at t he n e xt sc he d ule d d osi n g ti me. Partic i pa nt sw h o se 
dose le vel is t ole ra bil it y -li mit e d ma y  c o nti nue i n t he st u d y  f or t he i n te n de d d ura ti o n of t h eir 
as si g ne d c o h ort at t he ir o w n i n di vi d ual ma xi m u m t olerate d d o se ( MT D ), as j u dge d t o be 
a p pr o pr iate b y the PI  a n d s p o ns or . F or C o h o rts wi th a sta ble d osi n g p eri o d , d ose 
adj u st me nts/ti tra ti o n will not be p er mit te d d u ri n g t his pe ri o da n d pa rt ici pa nt ss h o ul d r emai n 
on t he sa me d os e(e v en if l o w er t ha n t he tar g et d ose ). 
T a ble 9. S a m ple Tit r at i o n S c he me a n d Dosi n g P ar a di g mfor St u d y P a rt A
C o h or taSt u d y D a y
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 t hr o u g h 2 8 b
1 1 0 m g 1 0 m g 1 0 m g 1 0 m g 1 0 mg 1 0 m g 1 0 m g 1 0 m g 
2 1 0 m g 1 0 m g 2 0 mg 2 0 mg 3 0 m g 3 0 m g 3 0 m g 3 0 mg 
3 1 0 m g 2 0 m g 3 0 m g 4 0 m g 5 0 m g 6 0 m g 8 0 m g 1 0 0 m g or MT D c
4 1 0 m g 3 0 m g 5 0 m g 8 0 m g 1 0 0 m g 1 2 0 m g 15 0 m g 2 0 0 m g or M T Dc
5 1 0 m g 3 0 m g 5 0 m g 1 0 0m g 1 5 0 m g 2 0 0 m g 2 5 0 m g 3 0 0 m g or M T D c
N O T E t h at t his is pr o vi de d a s a sa m ple o n l y. Ot her t ha n f or Part A, C o h ort 1, t he titrat io n sc he m e a n d ta r ge t 
dos ele vel f or eac h c o h ort will be pr o vi de d t o t he i n vesti gat or(s) i n wr iti n g pri or t o i nitiati o n of ea c h c o h ort. 
a. D os es a n d d ose ti trat i o n a p pr oac h es f or a d diti o nal c o h ort s/s t u d y  parts t o be deter mi ne d .
b. Sta ble d o se t o be a d mi n ister e d fr o m at lea st Da y 1 5 t hr o u g h 2 8 .
c. For parti ci pa n ts n ot a ble t o reac h t o tar get d ose of t ha t c o h ort , t h ei n di vi d ual M T D f o r tha t partic i pa nt ma y 
be p er m it te d .
F or all d osi n g a n d titrati o n re gi me n s, matc h i n g plac e b o wi ll als o be a d mi nistere d. 
 
 
 
 
 
 
 
 
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-[ADDRESS_455895] completed t he study if he/she has completed all phases of 
the study, including the last sche duled procedure shown in the Schedule of Activities .
The end of the study is defined as the date the investigator reviews the last participant’s final
data and determines that no further evaluation is required for the participant to complete thetrial.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled. The
following eligibility criteria are designed to select participants for whom participation in the 
study is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whethe r a particular participant is suitable for this 
protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the s tudy only if all of the following criteria apply:
Age and Sex:
1. Male and female participants must be between the ages of 18 and 70 years, inclusive,
at the time of signing the informed consent document (ICD). Females must be ofnon-childbearing potential.
•Refer to Appendix 4 for reproductive criteria for males ( Section 10.4.1 ) and 
females ( Section 10.4.2 ).
Type of Participant and Disease Characteristics:
2.Parts A and C only: Participants enrolling with T2DM must be taking metformin
monotherapy as their only anti-hypergly cemic treatment. Metformin dose must be at
least [ADDRESS_455896] 2 months prior to the screening visit. For further information, see Section 6.5 .
3.Parts A and C only: For participants enrolling with T2DM : HbA1c ≥7.0% and
≤10.5% at screening (confirmed by a single repeat, if necessary).  
Part B only: For participants enrolling as non-diabetic obese : HbA1c <6.5% at 
screening.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 364. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.
Weight:
5. A total body weight >50 kg (110 lbs).6.Parts A and C only: For participants enrolling with T2DM : body mass index (BMI)
of ≥24.5 to ≤45.5 k/m
2.
7.Part B only: For participants enrolling as non-diabetic obese : BMI >30.5 to
≤45.5 kg/m2.
Informed Consent:
8. Capable of giving signed informed consent as described in Appendix 1 ,w h i c h  
includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
1. Evidence or history of clinically significa nt hematological, renal, endocrine, 
pulmonary, gastrointestinal, hepatic, psyc hiatric, neurological, dermatological, or
allergic disease (including drug allergies  but excluding untreated, asymptomatic, 
seasonal allergies at the time of dosing).
•Participants who have chronic conditions other than T2DM and obesity (for 
example, hypercholesterolemia or hyper tension) but are controlled by [CONTACT_364949] 2 or fewer medications may be included (for example, aparticipant with hypercholesterolemia on appropriate treatment is eligible).  See Section 6.5 for further information on concomitant medications.
2. Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes.3.Part B only : Participants enrolling as non-diabetic obese may not have medical
history of type 2 diabetes mellitus.
4. Evidence or history of clinically significant cardiovascular disease. In particular, 
history of myocardial infarction, unstable an gina, arterial revascularization, stroke,
[LOCATION_001] Heart Association Functional Cl ass II-IV heart failure, or transient
ischemic attack within 6 months of screening.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 3 7 5. A n y  m al ig n a n c y  n o t c o nsi de re d c u re d (e x ce pt b asa l ce ll carci no ma an d s q u a mo us ce ll 
carci n oma of t h e s ki n); a part ici pa n t i s c o ns i d ere d c ure d if t he re ha s b e e n no e vi de n ce 
of ca ncer r e c urre nce i n t h e pr e vi o us [ADDRESS_455897] u g a bs or pt i o n (e g, pri or ba ria tric sur g er y , 
gast rect o m y, or a n y a r e a o f i n testi nal re sec ti on, act i ve i n fla m mat o r y  b o we ldisease or 
pa n creatic i ns uf fic ie nc y ). 
9. Pers o nal or fa mil y  hist or y of m e d ulla r y t h y r oi d ca rci n o ma (M T C) or m u lti p le 
e n d o cr ine ne o p lasia s y n dr ome t y p e 2( M E N 2) , o r pa rtic i pa nts wit h s us pe cte dM T C 
pe r t h e i n ves ti ga t or’s j u dge m e nt. 
 
1 1. Ot he rac ute o r c hr o n ic m edi cal or p syc hi at ric c o n diti o n i ncl u d i n g rece nt (wit hi n t he 
pa st ye ar ) or act i ve s u ici dal i d eati o n o r b eha v i or or la b orat or y a b n or m alit y t hat m a y 
i n cr ea se t h e ris kass oci a te d w it h st ud y par ti ci p ati o n or I P a d m i n ist rat i o n o r m a y  
i nte rfe re wit h t he i nt er pre tat i o n of s tu d y  re s ul ts a n d, i n t he j u d g me nt o f t h e 
i n ves ti ga t o r, w o ul d ma ke t he par tic ipant ina p pr o p ria te f or e ntr y i nt o t h isst ud y .
Pri o r/C o n c o m it a nt T he r a p y: 
1 2. See i n cl u si o n cr it eri o n # 2, e xcl u si on criteri o n #1a n d Secti o n 6. 5 f or de tai ls o n 
c o nc o m ita nt m e dicat io ns. 
Pri or/ C o n c urre nt C li ni cal St ud y E x p eri ence: 
[ADDRESS_455898] u g wit hi n 3 0 da ys ( or as det er mi ne d 
b y  t he local re qui r e me n t) or [ADDRESS_455899] u d y ( w hi c he ver is lo n ger) .
1 4. K n o w n pr i or par tic i p ati o n (ie , ra nd o miz ed a n d rec eive d at lea st [ADDRESS_455900] ) i n a trial i n v ol v i n g P F- 0 7 0 8 1 5 3 2 .  N ote t hat a gi ve n 
i n di vi d ual ma y  o nl y p artic i pa te i n 1 C o h o rt/ Part of t his st u d y . 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 38Diagnostic Assessments:
15. A positive urine drug screen at screeni ng or admission. Participants who have been 
medically prescribed benzodiazepi[INVESTIGATOR_364936] b e allowed to participate if approved by [CONTACT_130376].
16. Positive testing at screening for human immunodeficiency virus (HIV), hepatitis B 
surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis B surfaceantibody (HBsAb) or hepatitis C antibody (HCVAb).  As an exception a positiveHBsAb due to hepatitis B vaccination is permissible. 
17. Screening supi[INVESTIGATOR_9204] (BP) ≥160 mm Hg (systolic) or ≥100 mm Hg
(diastolic) following at least [ADDRESS_455901]. 
If BP is≥160 mm Hg (systolic) or ≥100 mm Hg (diastolic), the BP should be
repeated 2 more times and the average of the 3 BP values should be used to determine 
the participant’s eligibility.
18. Screening 12-lead electrocardiogram (ECG ) that demonstrates clinically relevant
abnormalities that may affect participant safety or interpretation of study results 
(eg, baseline Fridericia-corrected QT [QTcF] interval >450 msec, complete left
bundle branch block [LBBB], signs of an acu te or indeterminate-age myocardial
infarction, ST-T interval changes sugges tive of myocardial ischemia, second- or 
third-degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias).  
If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 
2 more times and the average of the 3 QTcF or QRS values should be used to
determine the participant’s eligibilit y.  Computer-interpreted ECGs should be
overread by a physician experienced in reading ECGs before excluding participants.
19. Participants with ANY of the following abnormalities in clinical laboratory tests at
screening, as assessed by [CONTACT_1758]-specif ic laboratory and co nfirmed by a single
repeat test if deemed necessary:
•Aspartate aminotransferase (AST) or a lanine aminotransferase (ALT) level 
≥1.5 times the upper limit of normal (ULN);
•Total bilirubin level ≥1.[ADDRESS_455902]; participants with a history of Gilbert’s
syndrome may have direct bilirubin measur ed and would be eligible for this study 
provided the direct bilirubin level is ≤ULN;
•TSH > ULN;
•Fasting C-peptide <0.8 ng/mL;090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 3 9 Se r u m calcit o n i n > UL N; 
A m yl as e> U L N; 
Li pas e > U L N .
2 0. P arts A a n d C ( partici pa nts wit h T 2 D M ): Fa sti n g bl o o d gl uc ose > 2 7 0 m g /d L at 
scree ni n g or a d missi o n , c o nfi r me d b y a si n gle re pe at test if dee me dneces s a r y .
2 2. At Scre e n i n g, par ti ci p a n ts wi th a n esti ma te d gl o m e r u la rfi ltr ati o n ra te ( e G F R) 
< 6 0 m L/ mi n / 1. 7 3 m 2asca lc ulate d b y t he m o d ific ati o n o fdie t i n re na l disease 
e q ua ti o n ( M D RD, see A p pe n di x 2 :Cli ni cal L a b orat or y  Te st s), a n d c o nfir me dvia a 
si n gle re p eat, if dee me d nec ess ar y .
Ot her E xcl us i o ns: 
[ADDRESS_455903] o r y o f alc o h ol ab u se or bi n ge d ri n ki n g a n d / or a n y  illi ci tdr u g use or de pe n de nc e 
wit hi n [ADDRESS_455904] i n k in g is defi ne d as a patter n of 5 ( mal e) a n d 
4(f e m ale) or m o re alc o h oli c dri n k s i n ab o ut 2 h o u rs.   As a ge n eral r ule, alc o h o l 
i n ta ke s h o ul d n ot e x c ee d 1 4 u nit s per we e k ( 1 u nit = 8 o u nc es ([ 2 4 0 m L ]beer, 1
o u nc e [3 0 m L ] of 4 0 % s pi [INVESTIGATOR_107060] 3 o u nc es [9 0 m L] of wi n e). 
2 4. Bl o o d d o nati o n (e xcl u di n gplas ma d o nati o n s) of a p pr o x i m atel y  1 pi [INVESTIGATOR_11731] ( 5 0 0m L ) o r 
more wit hi n [ADDRESS_455905] u d y .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 0 5. 3. Lifes t yl e C o n si de r ati o ns 
T he f oll o wi n g g ui d e li n es are pr o v i d e d: 
5. 3. 1. Me als a n d Diet ar y Re strict i o ns 
Pa rt ic ipa n ts m ust a b st ai n fr o m all f o o da n d dri n k ( e xce pt wa te r) at le ast 8h o urs pr i o r
t o t h e firs t bl o o d sa m ple at t he o ut pat ie n t Scree ni n g a n d f ol l o w- u p vis it s. 
Partici pa nts are re q u ire d t o f as t f or 4h o urs ( e x ce pt wa ter )pr i or t o a d missi o n t o C R U .
Part ici pa nt sm ust a bsta i n fr o mall f o o d a n d d ri n k ( e x c e pt wa te r) at lea st 8h o urs pri or 
t o t he fi rst bl o o d sa m ple o n i n p atie nt st u d y  da y s [ e g, for fi n gers tic k bl o o d gl uc ose 
( F S B G), safe ty la b o ra t or y, P K, assess me nt ]. 
N o nc af fei n ate d dr i n ks (e x c e pt as i n dicate d be l o w) ma y be c o n s u me d wit hmea ls a n d 
t h e eve ni n g snac k.   
Par tic i pa nts wil l refrai n fr o mc o ns u mi n g re d wi n e, gr a pe fr u it, or 
gra pe fr ui t- rel at e d c itr us fr ui ts (e g, Se vi lle or a n ges, po me l o s, f r ui t j ui ces) fr o m 
7da y spri or t o t h efirs t d os eof i n vesti gati o na l pr o d u ct u ntil c oll ec ti o n o f t he fi n al 
P K bl o o d s am pl e.
T he i n it ial ca l ori c i nta ke/ me n u ass i g ne d t o eac h p ar ti ci pa n t will be b ase do n t he 
Harris Be n edic tf or m ula (se d e nt ar ylifes t y l e ;t o be pr o v i de d t o t he s ite p ri or t o st ud y 
start) usi ng t he partici pa nt’ s b o d y  wei g ht meas u re d at scr ee ni n g. 
Bre a k f ast wi ll be pr o vi d e d at ap pr o x i matel y  0 8 0 0 h o urs o n ea c h i n pa tie nt da y: 
Ast an dar dbrea kfast will be p r o vi d e d f or c o ns u m pti o n a ft er dosi n g o n al l d a y s 
 
Lu n c h wil l be pr o v i de d a p pr o x i mate ly 4h o urs a ft er d o si n g (a p p r o xi mat el y 
1 2 0 0 h o urs )a n d a t a p pr o x i ma te l y t he s a me ti me o n eac h i n pa ti e nt d a y .
Di n n er wil l b e pr o v ide d a p pr o xi ma tel y  1 0 h o ur s af ter d os i n g (a p p r o xi mat el y 
1 8 0 0 h o u rs) and at a p p r o xi matel y the s a m e ti me o n eac h i n pat ie nt d a y .
A n e ve ni n g s n ac k ma ybe pe r mitte d at a p p r o x ima tel y 2 2 0 0 h o urs 
. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 1  
 
 
 
 
 
 
 
 
 
 
 
 
5. 3. 2. Alc o h ol, C af fei ne a n d T o b a cc o 
Pa rt ici pa nt s w ill a bst ai n fr o m alc o h ol f or 2 4 ho urs ( o r as s pecifie d a b o ve f or r e d 
wi n e) pri o r t o a d mi ssi o n t o t h e cl inic alre sea rc h u ni t ( C R U) a n d c o nti n ue a bstai ni n g 
fro m alc o h ol u ntil c ol lec ti o n of t h e fi na l bl o o d sa m ple at t h e f o ll o w- u p v isit . 
Pa rti ci pa nt s ma y u n d er g o a n alc o h o l b reat h te st or bl o o d alc o h ol t est at t h e discreti o n
of t he i n ves ti gat or. 
Caffei ne -c o ntai ni n g pr o d uct s, u p t o t he equi v ale nt o f t w o 8 - o u n ce c u p sof c o ff ee per 
da y , will be pe r mi tt e d .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 2 H o we ver, parti ci p a n ts m u st a bs ta i n fr o m ca ffei ne- c o nt ai n in g pr o d ucts for a
mi ni m u m of [ADDRESS_455906] u d y  partici pati o n ( fr o m scre e ni n g t o t h e fi nal f o ll o w- u p visi t) .  
  
 
 
Par ti ci p a nts ma y use t o bac c o- o r n ic ot ine- c o ntai ni n g pr o d u c ts as p er mitte d b y  t h e 
C R U (e g ,d ur i n g s m o k ing b rea k s, or i n spec ifi e d locati o ns) .
H o w e ver, s m o ki n g ma yn o t b e pe r mitte d w he n it w o ul d i n ter fe re wit h t he ti mi n g of 
sc he d ul e d st u d y  pr oce dure sor d u ri n g fr e q ue n t s a m pli n g pr o ce d ures In
a d dit ion,par tici p a nts m ust a bst ai n fr o m use of t o bac c o -or ni c o ti ne- c o n ta ini ng 
pr o d uct s:
F or a m i n im u m of 2 h o ur s pr i or t o all vital s i g n a n d E C G mea s u re me nt s; 
F or a mi ni m u m of [ADDRESS_455907] i v it y 
Par tici pa nts will a bs tai n fr o m stre n u o us e x erc ise ( e g, h e a v y li ft i n g, w ei g ht trai ni n g, 
ca lis t h e ni cs, a er o bi cs) f o r a t l east [ADDRESS_455908] s.   Wa l ki n g at a n o rmal p ace wil lbe per mit te d. 
Tosta n d ar diz e t he c o n diti o ns o n P K sa m pl i n g da ys, par ti ci pa nt swi ll be re q ui re dt o 
re fr a i n f r o m l y i n g d o w n (exce pt w h e n re q uir e d f o r B P, p ulse r at e, a n d E C G
me as ure me n ts), e ati n g, a n d dri n k i n g be v er a ges o the r t h anwa t e r d u ri n g the f irs t 
[ADDRESS_455909] e d an a p pr opriate met h o d of c o n tra ce pti o n f or t h ei n d i vi d ual 
ma le pa rti ci pa nt a n dhis par t n er (s) fr o m t he per m itte d li st of c o nt ra ce pti o n me th o ds (s ee 
A p pe n di x4,Secti o n 1 0. 4. 4 ) a n d wi ll c o n fi rm t ha tthe pa rt ici pa nt has b e e n i ns tructe d i n its 
c o ns ist ent a n d c orre ct use . At ti me p oi nts i n di cate d i n the Sc he d ule of A c ti vities , t he 
i n vesti gat or or d esi g nee wil li n f or mt he m al eparti ci p a nt o f t he ne e d touse effe ct i ve 
c o nt race pt i o n c o n si ste ntl y  a n d c o rre ctl y a n d d oc u m e n t t he c o n ve rs ati o na n d the male 
parti ci pa nt ’s af fir mat i o n i n t he pa rt ici pa nt ’s c h a rt ( p artici pa nts ne e d to affi rmt he ir c o nsi st e n t
a n d c o rr ec t use of a t least [ADDRESS_455910] e d met h ods of c o ntr ac e pt i o n) .I n a d dit io n, t he 
i n ve st i ga t or or desi g ne e wil l i n str uct t h e pa rt ici p a nt t o ca ll i m me diat el y if t h e select e d 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 3 c o ntrace pt i o n me t h o d is di sc o nti n ue d o rif pre g n a nc y  is k n o w n or s us pe cte d i n t h e
pa rt ici p a nt’s fe male part ner. 
Fe mal e par tici p a nts will n ot re q ui re use of c o nt rac e pti o n as t he y  ca n n ot be w o m e n of 
c h il d beari n g pot e ntial. 
5. 4. Scr ee n F a il ures 
Sc ree n fail ur es are defi n e d as par tici pa n ts w h o c o ns e n t t o p ar tici pat e i n t h e cli n ic al st u dy b ut 
are n o t s u bse q ue n tl y  r a n d o m ly as si g ne d t o i n v est igat io nal p r o d uct /e ntere d i n t he st u d y. A 
mi ni ma l se t of s cre e n fail ure i n for ma ti o n is re q uire d t o e n s u re tra n s p are nt re p or ti n g of scre en 
fail ure pa rti ci pa nt s t o me et t he Co ns o li d at e d St a n dar d s of R e p orti n g T ri al s( C O N S O R T) 
pu bli shi n g re q u ire m e n ts a n d t o r es p on d t o q uer ies fr o m re g ulat o ry a u t h o riti es. Mi ni mal 
i n f or ma ti o n i nc l u d es de m o gra p h y,  scree n f ail ure detail s, el i g i bilit y criteria, a n d a n yseri o us 
a d ve rs e e ve nt ( S A E) .
I n di vi d ual s w h o d o n ot mee t the cr it er i a f or partici pati o n i n t hi s st u dy(s cre e n fai l ur e) m a y  
n ot be rescree ne d, 
 
6. S T U D Y IN T E R V EN TI O N
St u d y  i n te r ve nt i o n is de fi ne d as a n y i n vesti gat i o n al i n ter ve nt i o n (s ), m ar kete d pr o d uc t(s ), 
pl ace b o, o rme di ca l d e v ice(s )i nte n de d t o be a d mi ni st er ed t o a st u d y p a rti ci pa nt ac cor di n g t o 
t he st u d ypr ot o c o l. 
For t he p ur p os es o f t h is pr ot oc ol, t h e ter m in ves ti ga ti o nal pr o d uc t m ay be use d 
s y n o n y m o us l y  wi t h st u d y i n ter ve nt i o n .
6. 1. St u d y I nter ve nti o n (s) A d m inist ere d 
F or t hi s s t u d y , t he i n ve sti ga ti o na l pr o d u c t is P F- 0 7 0 8 1 5 3 2 ( or m atc hi n g place b o). 
P F -[ADDRESS_455911] ie d t ot he C R U i n b ul k al o n g wit h i n di vi d ual d osi n g c ontai ners f or u nit 
d os i n g. 
6. 1. 1. Ad m i ni str a ti o n
O n Da y 1 , par ti ci p a n ts wi ll re ce i v e I P at a p pr o xi m at el y 0 8 0 0 h o urs ( p l us or mi n us 2 h o urs ).   
Deta il s o n meal sa n d dieta r y re q uir e m e nts a n d acti v it y re strict i o ns a re gi ve n i n Secti o n 5. 3 .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 4 P F - 0 7 0 8 1 5 3 2or a ls ol u ti o n :I P (i e, P F- 0 7 0 8 1 5 3 2 a n d pla ce b o) will be a d mi nistere d 
ac c or di n g t o t he e xt e m p ora ne o us di s pe nsi n g r e c or d( E D R). I n vest igat or si te pers o n ne l will 
a d mi n ist er i n v esti g at i o nal pr o d uc t wit h a m b ie nt t e m pe ra t ur e wat er t o a t otal v o l u me of 
a p pr o xi mate l y 2 4 0 m L ( [ADDRESS_455912] us a p pr o xi ma te l y 1 4 0 m L 
ri nse) .  T he e nt ire vol u me of li q u i d m ust be c o n s u me d by t he p a rtici p a nt. 
P F - 0 7 0 8 1 5 3 2T a blet f or m ul ati on: I n v esti ga tor site pers o n ne l will a d mi nister i n vest i g at i o nal 
pr o d uc twit h a p pr o xi ma te l y [ADDRESS_455913] pri or t o swal l o w i n g . 
 
  
Metf or mi n a n d ot her Per mitte d C o n c o mit a nt Me di c at i o ns :O n al l st u d y d a y s w hile i n t he 
CR U , partici pa nt swi ll be gi ve n t he ir m or n i n g d os e o f me tf or m i n at t he sa me t i me a s 
P F- 0 7 0 8 1 5 3 2/ p lace b o.
Pa rt ici pa nt s wi ll n ot be pr o vi d e d wit h met f or mi n duri ng t he st ud y .  Parti ci pa nts enr olle d i n 
Parts A a n d C of t h is st u d y are e x pe cte d t o bri n g t h eir c u rr e nt s u p pl y  of metf or m i n pri or t o 
co nf i n e m e nt t o t he unit .
F or partic ipa nts ta ki n g metf or mi n m ore f re q ue ntl y  t ha n o nce a da y , t he i n v es ti gat or w ill 
det er mi n e t he a p pr o pr iate ti mes d ur i n g t he da y  t o a d mi nis ter t h o se d oses .  F or metf or m i n 
(re q u ire d )a n d ot h er per mit te d c o nco mit a nt me dicat i o ns, t he ti mi n g of ad mi nis trati o n s h o ul d 
be t he sa me bet wee n i n pati e nt d ays , a n d c are s h o ul d be ta ke n t o mi ni miz e c ha n g es t o t he 
parti ci pa nts sta ble me dicati o n r o u ti ne .  
6. 2. Pr e p ar ati o n / H a n dli n g/ St or a ge /Acc o unt a bi lit y 
1. T he i n ve sti ga t o r or des ignee m us t c o nfir m a p pr o pri ate te mper at u re co n di ti o ns ha ve 
bee n mai nta i ne d d ur in g t ra nsit f or all st u d y i nte r v enti o ns r ecei ve d a n da n y
di scre p anci es are re p or te d a n d r es ol ve d b ef ore u se of t h e st u d y inter ve n ti o n,as 
a p plic a bl e f or te m pe rat ur e- m o n it ore d s hi p m e nts .
2. O n l y  par ti ci pa n ts e n r o ll e d i n t he s t u d y ma y  recei v e st u d y i nt er ve nti o n a n d o nl y  
aut h or ize d sit e sta ff ma y s u p pl y  o r a d mi niste r s t u d y  i nte r ve nti o n. Al l st u d y 
i nter v e n ti o n sm u st be st or e d i n asec ure , e n vi r o n m ental ly c o n tr olle d, a n d m o nit or e d 
( m an u al or a ut o m ate d rec or di n g) ar ea i n ac c or da n c e wi t h t h e la b el e d st ora ge 
c o n diti o ns w it h acc ess li mite d t o t he i n ve st i ga tor a n d a ut h oriz edsite staf f. At a 
mi n im u m, dai l y  mi n i m um a n d ma xi m u m te m perat ur es f or all si te s tora g e l oca ti o ns 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-[ADDRESS_455914] 
indicate the minimum and maximum temperat ure since previously documented for all
site storage locations upon return to business.
3. The investigator, institution, or the head of the medical institution (where applicable)
is responsible for study intervention accountability, reconciliation, and record
maintenance (ie, receipt, re conciliation, and final disposition records). All study
interventions will be accounted for using an IP accountability form/record.
4. Further guidance and information fo r the final disposition of unused study
interventions are provided in the study documentation.
5. Any storage conditions stated in the SRSD will be superseded by [CONTACT_364950].
6. Study interventions should be stored in th eir original containers and in accordance
with the labels.
7. See the extemporaneous dispensing record (EDR) for storage conditions of the study 
intervention once reconstituted and/or diluted for administration as an oral solution, or the investigational product manual if oral tablets are provided.
8. Deviations from the storage requirements, including any actions taken, must be 
documented and reported to [COMPANY_007] upon discovery. The site should actively pursueoptions for returning the study interventi on to the storage conditions described in the 
labeling, as soon as possible. Once an excursion is identified, the study interventionmust be quarantined and not used until [COMPANY_007] provides permission to use the study intervention. It will not be considered a pr otocol deviation if [COMPANY_007] approves the use 
of the study intervention after the temperature excursion. Use of the studyintervention prior to [COMPANY_007] approval will be considered a protocol deviation. Specific
details regarding the definition of an excursion and information the site should report for each excursion will be provided to the site in the study documentation. 
9. The sponsor or designee will provide guidance on the destruction of unused study
intervention (eg, at the site). If destruct ion is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destroyed incompliance with applicable environmental reg ulations, institutional policy, and any
special instructions provided by [CONTACT_4618], and all destruction must be adequately 
documented.
Additional details about accountability, storage, destruction, and excursion reporting can be 
found in the IP manual.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -[ADDRESS_455915], 
co n c o m it ant t rea t m e n ts, a n d a cc o m p a n yi n gi nf or ma ti o n b y qualif ie d sta ff me m b er (s) t o a 
hea lt hcare pr o vi de r, partic i pa nt i n acc or d a nc e wit h t his pr o toc o l.  L ocal he alt h a u th orit y 
re g u lat i o ns o r i n vesti ga t o r s ite g ui de li n es ma yuse alte r n ati ve ter m s for t hese acti vit ies. 
P F - [ADDRESS_455916].   D o ses will be pre pa re d b y q u alifi e d u nbli n de d site 
pe rs o n ne l.  Bli n de d IP will b e a dmi nis ter edt o the pa rtici p ant.   Deta ils o fd os e pre pa rat i o n 
wil lbe g i v e n i n a s e pa r a t e e x te m p o ra ne o us di s p endi n g re c or d ( E D R ). P re p a re d d oses wi ll be 
pr o vi de d in u n it d os ec o n tai ner s a nd la bele d in acc o rda n ce wi t h P fiz er re g u lati o ns a n d t he 
in ves ti g at or sit e’ s la b eli n g r e q u ir e me nt s. 
PF- [ADDRESS_455917] u d y  staff (e g, p h ys icia n, n urs e, p h y sic ia n’s assist a nt, n urse pr actiti o n er, 
p har mac y as si sta nt /t ec h n icia n, o r p har macis t) .  T h e ta ble ts wi ll be pr o vi de d i n u ni t d o se 
c o ntai ners a n d la be le d i n ac c or da nc e wi t h [COMPANY_007] re gulat io ns a n d t he cli nica lsi te’s la bel i n g 
re q uire me nts. 
 
 
6. 3. M e as ur es t o Mi ni mize Bi as: R a n d o m iz ati o n a n dBli n di n g 
6. 3. 1. Al l o c a ti o n t o I n ve sti g ati on al Pr o d uc t
Pa rti ci p a n ts will be ra n d oml y ass i g ne d t o recei ve i n ve st igat i o nal pr o d u ct fr o m a ce nt ral 
ra n d o m izati o n sc he me .  I n ve st i gat ors w ill r ema in bl i n de d t o ea c h pa rti ci p a nt’s assi g ne d 
i n vest i g ati o n al p r o d u ct t h r o u g h o ut t h e c ours e of t h est u d y. I n or d er to m ai ntai nt h is bl i n d, a n 
ot h er wi se u ni n v ol ve d t h ird part y (f or exa m ple, p ha r ma cist ) will be res p o ns i b le f or t he 
pre parati o n a n d dis pe n si n g of all in vest igat i o nal pr o d uct acc o r di n g t o t h e r a n d o miz at i o n 
sc he d ul e a n d assi g ne d tr ea tme ntf o rt h e i n d i v id ual part ic i pa nt. 
Al l ocati o n of par tic i pa n ts t o trea t m e nt gr o u ps wi ll pr o cee d t hr ou g h t he us e of a n interact i v e
res p o nse tec h n o l o g y  (I RT) s y ste m (i n ter act i v e W e b -bas e d re s p o ns e [ IW R] ). T h e u n bli n d e d 
di s pe n si n g p ers o n ne l wi ll be r e q ui r e d t o e nter or s el ec t i nf or mat i o n i ncl udi n g b ut n ot li mi te d 
t o t he user’s ide n ti ficat i o n (I D) a n d pa ss w or d, t h e pr o toc ol n u m ber, a n dt he part ici pa nt 
nu m b er .  T he u n b li n de d d is pe nse r wil l t he n be p r o v ide d wi t h a ra n d o mi za ti o n n u m ber, 
pro d uct ass i g n m e nt ,a n d dis pe n sa ble u ni t ( D U) or c o ntai ner n u m ber w he n i n vesti g ati o nal 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-[ADDRESS_455918] information and further 
details on the use of the IRT system.
6.3.2. Breaking the Blind 
The IRT will be programmed with blind-breaking ins tructions. In case of an emergency, the 
investigator has the sole responsibility for de termining if unblinding of a participant’s 
treatment assignment is warranted. Participant saf ety must always be the first consideration
in making such a determination. If the investig ator decides that unblinding is warranted, the 
investigator should make every effort t o contact [CONTACT_1152] a 
participant’s treatment assignment unles s this could delay further management of the
participant. If a participant’s treatment assign ment is unblinded, the s ponsor must be notified
within 24 hours after breaking the blind. The date and reason that the blind was broken mustbe recorded in the source documentation and case report form (CRF).
The study-specific IRT reference manual and IP manual will provide the contact [CONTACT_22810].
Blinding codes should be broken only in exceptio nal circumstances when knowledge of the 
actual treatment code is absolutely essentia l for further management of the participant. 
Investigators are encouraged to discuss with a member of the study team if they believe thatunblinding is necessary.  When the blindin g code is broken, the reason must be fully
documented and entered on the case report form (CRF) /data collection tool (DCT).
Blood specimens will be obtained from all pa rticipants for PK analysis to maintain the study
blind at the investigator site.  Only the investigator site staff and blinded study monitor, if assigned, will be blinded to study treatment. Other [COMPANY_007] personnel will be unblinded to 
participant treatments in order  to permit real-time interpretatio n of the safety and PK data,
and provide information necessary to potentia lly alter the dose-escalation sequence. The
blinded study monitor, if assigned, will re main blinded to treatment until all monitoring for
the study has been completed. Specimens from  participants randomized to placebo will not 
be routinely analyzed for PF-07081532 PK.  To minimize the potential for bias, treatmentrandomization information will be  kept confidential by [CONTACT_364951].090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-[ADDRESS_455919] be made not to alter the doses and regimens of the background/c oncomitant medications after randomization 
and for the duration of participation in this study . Any changes must be captured in the CRF.
Where applicable, participants are expected to bring their supply of permitted prescription
medications prior to confinement to the unit.
Treatments taken within [ADDRESS_455920] be recorded withindication, daily dose, and start and stop dates o f administration. All participants will be
questioned about concomitant treatment at each clinic visit.
Medications, prescription or non-prescription, or herbal supplements not specifically listed
here may be permitted, but only after review and approval by [CONTACT_456].
6.5.1. Medications for Glycemic Control: Parts A and C only
All participants enrolling with T2DM (Parts A and C) are required t o be taking metformin
monotherapy. At screening, this study requires ( Section 5.1 ) that participants have been 
taking a minimum metformin dose of ≥500 mg/day for at least 2 months prior to the 
screening visit. The dose of metformin, where pos sible, is expected to remain the same until 
completion of study participation (ie, the Follow-up visit).
Use of other medications for glycemic control is not permitted in this study (see
Section 6.5.4 ).
6.5.2. Antihypertensive and Lipid-Modifying Agents: Parts A, B, and C
The use of background antihypertensive and/or lipid-modifying agent(s) is permitted (unless 
noted in Section 6.5.4 ). Doses of such agents must be stable for at least 4 weeks prior to
screening and are expected to remain th e same until completion of study participation 
(ie, follow-up visit).
6.5.3. Management of Nausea and Vomiting
Nausea and vomiting have been reported w ith administration of GLP-1R agonists. 
Participants experiencing such symptoms may  be managed conservatively with bed rest 
and/or fluid management at the discretion of the investigator. If the nausea and vomiting are not amenable to conservative management, anti-emetics (eg, prochlorperazine, promethazine,090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 4 9 on da nsetr o n ) m a y b e a d m i nistere d at t he i n vesti g at or’ s di screti o n wit h n otif icati o n t o t he 
s p o ns or a n d e nt r y  i n t he C R F .
6. 5. 4. Pr o hi bi ted Me dic ati o ns 
Me di c a ti o n s Not Per mitt edd ur i n g st u d y c o n d uct 
 
 
 
 
Me dic ati o ns Not P er mitte dwit hi n [ADDRESS_455921] u d y :
T h iaz o li di ne d io ne s ( T Z D s) s uc h as pi o gli taz o ne a n d r o si glitaz o ne; 
Su bc u ta ne o us l y a d mi nis tere d a ge nts f o r gl yc emic c o ntr ol (e g, i n s u li n , e xe nat ide, 
lira gl uti de, pr aml i nt i de). 
Me dic at i o ns N ot Per m itte d wi t hi n [ADDRESS_455922] u d y :
Ot her oral a nti - dia betic me dica ti o ns , i ncl u di n g: 
Sulf on y lureas s uc h as ace t o h e x ami de, c hl or pr o p ami de , t o laza mi de, tol b uta mi ne ;
Gli me pir i d e, gl i pi [INVESTIGATOR_146705], gl y b uri de; 
Me g lit i ni de a nal o g u es s uc h as re pa gli ni de, nat e gl ini de ;
Di pe pti d y lpe pti dase -4 i n hi bit or s ( D P P -4i) s uc h as sita g li pti n, sa xa g li pti n; 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 5 0 Vil da gl i p ti n; 
  -gl uc osi dase in hi b it ors s uc h as aca ra b ose , m i g lit o l; 
S o d i u m- g l uc ose c otra ns porter - 2 ( S G L T2) i n hi bit ors s uc h as ca na gl ifl ozi n .
Sys te mic gl uc o c orti c oi ds s uc h as pre d nis o ne, de x a met has o ne, tria mci n ol o ne ,
b u des o ni de, beta met has o ne .
N ote: As a n e xce pti o n, ster oi d -c o ntai ni n g i n ha lers, n asa l s pra ys, a n d topi [INVESTIGATOR_364937] m ul at i o ns ar eper mitte d.
I m m u n o s u p p r e ss a n ts s u c h as c y cl os p ori ne an d tacr o li m us .
A p peti te - o r wei g h t-m o dif y i n g me dicati o n s, i ncl u di n g n o n -prescri pt i o n or her bals. 
P har mac ol o gical a ge n ts wit h a p pr o v e d i n di ca ti o n f or w ei g ht l o ss s u c h as orli stat a n d 
si b utr a mi ne .
( M edica l-gra de) m ar ij ua n a, re gar dl es s o fme dical i n dicati o n .
A nti- ps y ch otic me dica ti o ns s uc h a s ola nza pi [INVESTIGATOR_050] , ris peri d o ne. 
A nti de pressa nt me dica ti o ns s uc h as tric y clic a ge nts, sele cti ve ser ot o ni n re u pta k e
i n hi bit o rs , a n dser ot o ni n/ n or e p i ne p hr ine re u pt a ke i n h i b it ors .
C o u mari n-t y pe a nt ic oa g u la nt s o rot her a ntic oa g ula nt s(e g, da bi g atra n) .
A n tic o n v ulsa nt s, if prescr i be d f or a seiz ure dis or der .
O pi [INVESTIGATOR_27968] .
A ntiarr h yt h mic s.
N o n- selecti ve -bl oc kers .
T hi az i de d i ur etics > 2 5 m g per da y .
S y m pat h o mi metic a ge nts .
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 516.5.5. Rescue Medicine
There is no rescue therapy to reverse adverse events (AEs) observed with PF-07081532;
standard medical supportive care must be provided to manage any AEs (see Section 6.5.3
Management of Nausea and Vomiting).
For medical management of hypoglycemia, the investigator may administer oral
carbohydrate, glucagon, or IV glucose according to his or her medical judgment. At aminimum however, treatment or administration of a scheduled meal should be given ifglucose falls <60 mg/dL for at least [ADDRESS_455923] bothersome symptoms of hypoglycemia along with glucose values of ≤70 mg/dL.
No rescue therapy will be provided for hyperglycemia. If a participant has sustained elevated
fasting plasma glucose concentrations that are >270 mg/dL on 3 consecutive measurementsover 3 days, that participant will be discontinued, and the investigator will recommendfurther appropriate glycemic treatment according to the local healthcare standards and national guidelines.
6.6. Dose Modification
6.6.1. Dose Escalation and Stoppi[INVESTIGATOR_364938]. Dose escalation may be stopped if it is determined that the limits of safety and/or tolerability have been reached. This decision will be made after a discussion takes place between the sponsor study team and the i nvestigator. The sponsor study team may not 
overrule the investigator’s decision to stop dose escalation.  If dose escalation is stopped because of any of these criteria, additional c ohorts may receive the same or lower doses of 
the investigational product.
The dose escalation will be terminated based on the following criteria:
•If 50% or more of the participants receiving active drug at a given dose level (but not 
participants receiving placebo) develop similar clinically significant laboratory, electrocardiogram (ECG), or vital sign abnormalities, in the same organ class, indicating dose-limiting intolerance.
•Severe nonserious adverse events (AEs), considered as, at least, possibly related to
investigational product administration, in 2 participants at a given dose level (but not participants receiving placebo), independent of within or not within the same systemorgan class, indicating dose-limiting intolerance.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 5 2 D osi n g wi ll be p a u se d f or a n y seri o u s a d verse e ve nt ( S A E ) t hat occ urs i n a pa rtic i pa nt 
rec ei vi n g a ct i ve treat me nt u nt il ca usalit y  is f u ll y  as se sse d b y t h e pri nci pal i n ves ti gat o r
( PI) a n d s p o ns or.   D osi n g ma y  res u me if t h e S A E is deter mi ne d t o b e n o t dr ug-r elate d 
b y t h e PI [CONTACT_1629] d s p o ns or. If t h e S A E is de te r m i ne d t o be eit her dr u g- rel ate d or 
u n k n o w n, e it h er d o si n g will ceas eor t he S A E will be e va l u ate d b y t h e s p o ns or’s 
pr ot o c ol re vie w c o m m ittee ( or si mila r re vie w gr o u p), w h ic h is i n de pe n de nt of t h e 
st u d y tea m a n d i n ve sti gat o rs .  If t he p rot oc ol re vie w c o m mitt ee de ter mi nes t hat 
d osi n g m a y  res u me , a pla n t h at mi ti gat es ris ks t o partici pa nt s wi t h t he res u m pt i o n of 
d osi n g will be i m ple me nte d.  S uc h a pla n c o ul d i ncl u de a r e visi o n of 
i ncl usi o n/e xcl usi o n cri te ri a, r e peati n g or re d u ci n g t he d ose ,or a d di n g a p pr o p ri ate 
saf et y m o nit ori n g . 
It is det er mi ne d t ha t t he l i mit of s afet y  a n d /or t olera bilit y  h as bee n reac he d.   This 
decisi o n wil l be m ade f oll o wi n g disc u ssi o ns bet wee n t he st u d y  tea m a n d t he 
i n vesti gat o r. 
Ot h er fi n di n gs t ha t, at t he discreti o n of t he st u d y  tea m a n d i n ve sti gat or, i n dicate t h at 
dose es ca lat i o n s h o ul d be ha lte d .
If, at a n y d ose le vel , t he a v era ge ex p os ure reac hes or e xcee ds t he p har mac o ki neti c 
( P K) st o p pi n g li m its of: 
T hese st o p pi n g li mit s ar e b as ed o n t he u n b o u n d e x p os ures at t h e N O A E L i n t he 
n o n- h u m a n pri mate ( N H P )t o xicit y stu d y  (see Secti o n 2. 2. 3 )after a cc o u nti n g f or 
pr otei n bi n di n g i n h u ma ns. 
If, bas e d o n t h e o bser ve d data, t he gr o u p mea n ma xi mu m o bser ve d c o nce ntrati o n 
( C ma x ) or area u n der t he c ur ve ( A U C) (bas e d o n t otal pl as ma c o nce ntrati o n) of t h e 
ne xt pla n ne d d ose is pr o jecte d t o e xce ed t he e scalati o nli mits, t hat d ose will n ot b e 
e x pl o re d .  M o difi e d d ose s ma y  be e x p lore d i fthe y a re n ot e x p ecte d t o e xc ee d P K 
st o p pi n g criter ia. 
Pr o g r e ssi o n t o t he ne xt d o se w ill o cc ur if t he las t d o se was well t ol erate d a n d after 
satisfac tor y  re vi e w of the a vai la ble sa fe t y  a n d P K data. 
Data re q uire d f or d os e escalat i o ne va l uati o n will be det er m i n e d by c o h ort a n d will be base d 
o n re vie w of safet ya n d P K data t hr o u g h a mi ni m u m of [ADDRESS_455924] 7 of t he se da y s at t he pre vi o us tar get d ose le v el . E ac h d os e escalat i o n will be bas e d 
o n re vie w of a v aila ble safet ya n d P K data f or at leas t 7partic i pa nt s f r o m that c o h ort. Details 
o n safet y asses sme n ts i ncl u de d i n d ose escalat i o n r e vie w are pr o vi de d i n Secti o n 8. 2 a n d 
A p pe n di x 2.0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 53The timing of safety and PK required for dose escalation will be provided in writing prior to 
initiation of dosing for each such cohort.
6.7. Intervention After the End of the Study
No intervention will be provided to study participants at the end of the study.
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionThis is a multiple dose study in which study participants may receive up to [ADDRESS_455925]. Discontinuation of dosing does not necessarily represent withdrawal from the study (see Section 7.2 ). If investigational product is permanently discontinued, the 
participant may remain in the study to be evaluated for the remainder of the study. At a minimum, an early termination visit will be conducted. See the Schedule of Activities for 
data to be collected at the time of intervention discontinuation (early termination) and follow-up and for any further evaluations that need to be completed.  Additional follow-up 
may be required for safety evaluation, at the discretion of the investigator. 
ECG Changes A participant who meets either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from the study. 
•QTcF >500 msec.
•Change from baseline: QTcF >60 msec.
If a clinically significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the inves tigator or qualified designee will determine if 
the participant can continue in the study and if any change in participant management is needed. This review of the ECG printed at the time of collection must be documented. Any 
new clinically relevant finding should be reported as an AE.
See the SoA for data to be collected at the time of intervention discontinuation and follow-up 
and for any further evaluations that need to be completed.
Adverse EventsTreatment will be discontinued and the participant withdrawn from the study for:
•Treatment-related serious adverse events (SAEs);
•Other serious or severe AEs, at the discretion of the investigator or sponsor.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 54Laboratory Abnormalities
All of the following laboratory abnormalities require discontinuation if they are confirmed:
•Hyperglycemia: see Section 6.5.5 ;
•Creatine kinase >[ADDRESS_455926];
Note: Urine myoglobulin and serum creatinine (SCr) will be performed as reflex 
testing for any participant with creatine kinase >[ADDRESS_455927].
•AST or ALT that meets ANY of the following:
•>[ADDRESS_455928] one total bilirubin value >[ADDRESS_455929];
•>[ADDRESS_455930] accompanied by [CONTACT_364952]
[eg, new onset elevated prothrombin time/international normalized ratio 
(PT/INR)];
•Two sequential AST or ALT elevations >[ADDRESS_455931], regardless of total bilirubin or 
accompanying signs or symptoms.
NOTE: See also Appendix 6 for potential cases of drug-induced liver injury.  
Potential Cases of Acute Kidney InjuryAbnormal values in serum creatinine (SCr) conc urrent with presence or absence of increase 
in blood urea nitrogen (BUN) that meet the criter ia below, in the absence of other causes of
kidney injury, are considered potential cases of acute kidney injury and should be considered 
important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5μmol/L) in SCr level relative to the participant’s own 
baseline measurement should trigger anothe r assessment of SCr as soon as practically
feasible, preferably within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [or ≥26.5μmol/L] in SCr
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4μmol/L), the 
participant should be discontinued from the study and adequate, immediate, supportive measures taken to correct appa rent acute kidney injury.
Participants should return to the investigat or site and be evaluated as soon as possible, 
preferably within 48 hours from awareness of the second assessment confirming abnormal 
SCr result.  This evaluation should include laboratory tests, detailed history, and physical assessment.  In addition to repeating SCr, la boratory tests should include serum BUN, serum 
creatine kinase, and serum electrolytes (including at a minimum potassium, sodium, phosphate/phosphorus, and calcium), in addition to  urinary dipstick, urine microscopic 090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 55examination, and urinary indices.  All cases confirmed on repeat testing as meeting the 
laboratory criteria for acute kidney injury, w ith no other cause(s) of laboratory abnormalities
identified, should be considered potential cases of drug-induced kidney injury irrespective of 
availability of all the results of the investigations performed to determine etiology of the abnormal SCr.  If ≥[ADDRESS_455932] 
2consecutive SCr results of ≥0.3 mg/dL (or ≥26.5μmol/L), an assessment of whether the 
finding may be considered an adverse drug reaction should be undertaken.
Prohibited MedicationsParticipants who are treated with any prohib ited medication during the course of the study 
may require discontinuation.  Participants who are administered or take a prohibited medication should be discussed with the sponsor for possible withdrawal from the study.
7.2. Participant Discontinuation/Withdrawal From the Study
A participant may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the inve stigator for safety, be havioral, compliance, 
or administrative reasons.
At the time of discontinuing from the study, if possible, an early discontinuation visit should
be conducted. See the Schedule of Activities for assessments to be collected at the time of 
study discontinuation and follow-up and for any f urther evaluations that need to be 
completed. 
The early discontinuation visit applies only to participants who are randomized and then are 
prematurely withdrawn from the study.  Participants should be questioned regarding their reason for withdrawal.  
The participant will be permanently discontinued both from the study intervention and from
the study at that time.
If a participant withdraws from the study, he/she may request destruction of any remaining
samples, but data already generated from the samples will continue to be available, and may be used to protect the integrity of existing analyses. The investigator must document any such requests in the site study records.
If the participant withdraws from the study and also withdraws consent (see below) for 
disclosure of future information, no further evaluations should be performed and noadditional data should be collected.  The s ponsor may retain and continue to use any data 
collected before such withdrawal of consent.  When a participant withdraws from the study 
because of an SAE, the SAE must be recorded on the CRF and reported on the Clinical Trial (CT) SAE Report.
Lack of completion of all or any of the withdrawal/early termination procedures will not be
viewed as protocol deviations so long as  the participant’s safety was preserved.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 56Withdrawal of Consent: 
Participants who request to discontinue receip t of study treatment will remain in the study
and must continue to be followed for prot ocol-specified follow-up procedures.  The only
exception to this is when a participant specif ically withdraws consent for any further contact 
[CONTACT_22817].  Participants should notify the investigator in writing of the decision towithdraw consent from future follow-up, whenever possible.  The withdrawal of consent should be explained in detail in the medical records by [CONTACT_093], as to whether the withdrawal is only from further receipt of investigational product or also from studyprocedures and/or posttreatment study follow-up, and entered on the appropriate CRF page. In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately 
directed in accordance with local law.
7.3. Lost to Follow up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for
scheduled visits and is unable to be contact[CONTACT_9298].
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:
•The site must attempt to contact [CONTACT_364953]/or should continue in the study;
•Before a participant is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact [CONTACT_190365] e participant (where possible, 3 telephone
calls and, if necessary, a certified letter  to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_364954]’s medical record;
•Should the participant continue to be unreach able, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study as a whole is handled as part of Appendix [ADDRESS_455933] to confirm that they meet the study population criteria for the study.  The investigator (or an appropriate delegate at the investigator site) must obtain a signed and dated ICD
before performing any study-specific procedures .  If the time between screening and
dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug shipment), then 090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -[ADDRESS_455934] d o se 
ad mi nis trati o n me et eli gi bilit y criteria. 
A par tici pa nt w h o q ualifi ed f o r this p r ot oc ol b ut di d n ot e nr oll fr o m a n earlier c ohort / g r o u p 
ma y  be us e d i n a s u bse q ue n t c o h ort / gr o u p wit h o ut re sc ree n i n g, p r o vi d e d la b ora t or y  r es ults 
o btai ne d pri o r t o t h efi rs t d os e a d mi nistrati o n meet eli gi bi li t y  criteria f or t his st u d y .  
 
St u d y  pr oce dures a n d t heir ti mi n g are sum ma ri ze d in t he Sc he d ule of Acti vit ies . Pr ot oc ol 
wai vers or e xe mpti o ns are n ot all o we d. 
I m me dia t e saf et y  c o ncer ns s h o ul d be disc usse d wi t h t he s p o ns or i m me dia te l y u p o n 
occ urre nce or a ware ne ss t o deter mi ne if t he p art ici p a n ts h o u l d c o n ti n ue or dis c o nti n ue st u d y  
i nter ve nti o n. 
A d here n ce t o t he st u d y desi g n r e q uire m e n ts, incl u di n g t h ose s pec ifie d i n t h eSc he d ule of 
Acti vi ties , is ess e ntial a n d re q ui re d for st u d y  c o n d u ct. 
All sc ree n i n g e val uati o ns m ust be c o m plet e d a n d re vie w e d t o c o nfir m t hat p ote nt ial 
parti ci pa n ts meet all eli g i bilit y  criteria . T he i n ve st i gat or will mai nt ai n a scree n i n g l o gt o 
rec or d details o f al lpart ici pa nts scre e ne d a n d t o c o nf ir m eli gi b ilit y or rec or d re as o ns for 
scree ni n g fail ure, as a p pl ic a bl e. 
E ver y eff ort s h o ul d be ma de t o e ns ure t hat p rot oc ol -r e q u ire d tests a n d pr oce d ur es ar e 
c o m plete d as d escri b e d.  H o we ver , it i sa ntici pate d t hat fr o m t ime t o ti me t he re m a y  be 
circ u msta n ces outsi d e t he co n tr o l of the i n ve sti gat or t hat ma y  ma ke it u nf ea si b le t o pe rf or m 
t he test .  I n t h ese cases, t he i n vesti ga t o r m ust ta ke all ste ps n ece ssar y t o ens ure t he s afet y a n d 
well -bei n g of t h e partici pa nt.  W he n a pr ot oc ol-r e q uir e d t est ca n n ot be pe rf or me d, t he 
i n ve st i ga t or wi ll d o c u me nt t he reas o n f or t he misse d tes t a n d a n y c orrecti ve a n d pre ve nti ve 
acti o n s t ha the or she has ta ke n t o e ns ure t ha t re q uir e d pr oce sses are a d h e re d t o as s o o n a s
p ossi ble.  T he st u d y te am m us t be i n f o r me d of t hese i nci de nts in a t i mel y ma n ner .
Al l eff ort swi ll be ma de t o c o n d uct pr oc e d ures at t he e xact n o mi nal ti me relat i v e t o d osi n g.  
Pr oc e d ures u p t o a n d i ncl u di n g 1 0 h o urs aft er d ose a d mi nistr at i o n t h at are c o n d u cte d wit hi n 
1 0 % of t he n o mi na l ti me (e g, wit hi n 6 mi n ut es of a 6 0- mi n ute sa m ple) rel ati ve t o d osi n g will 
n ot be ca pt ure d a s a pr ot oc ol de viati o n, as l o n g as t he e xact ti me of t he pr oce d u re is n ote d o n 
t he s o urce d oc u me n t a n d data c ollecti o n t o o l ( e g, C R F / D C T ).   Pr oce d ures sc he d ule d m o re 
tha n 1 0h o urs af ter dose a d mi n istrati o n t ha t are c o n ducte d ≤ [ADDRESS_455935] ti me 
of t he pr oce d ure is note d o n t he s o ur ced oc u me nt a n d data c ollecti o n t o o l (e g , C R F/ D C T ). 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 58When multiple procedures are scheduled at the same time point(s) relative to dosing, the 
following chronology of events should be adhered to, where possible:
•ECGs : obtain prior to vital sign measurements and as close as possible to the
scheduled time, but prior to blood specimen collection (refer to Section 8.2.3 );
•Vital Signs (BP and pulse rate) : obtain as close as possible to the scheduled time, but
prior to blood specimen collection (refer to Section 8.2.2 );
•Weight : obtain as close as possible to the scheduled time, but prior to eating and 
drinking and prior to dose administration, where applicable (refer to Section 8.6.3 );
•Fasting blood samples : after assessment of 12-lead ECG and vital signs but prior to
dosing;
•PK blood specimens : obtain at the scheduled time (for 0H samples, collect before 
dosing and as close as possible to dosing time, where applicable);
•Dosing : must occur at the scheduled nominal time and following predose blood 
sample collection;
•Breakfast : provided for consumption following dosing, where applicable (see 
Section 5.3.1 ).
Note that if an IV catheter is placed for serial blood sample collections, ECGs and vital signs
(pulse rate, BP) assessments should be either collected prior to the insertion of the catheter or sufficient rest period after catheter insertion introduced to minimize impact of catheter placement on these assessments.
For samples being collected and shipped, deta iled collection, processing, storage, and 
shipment instructions and contact [CONTACT_22819].
The total blood sampling volume for individual participants in Part A of this study is
approximately 535 mL.
The total blood sampling volume for individual participants in Part B of this study is 
approximately 420 mL. 
The total blood sampling volume for individual participants in Part C of this study is 
approximately 525 mL.
The actual collection times of blood sampling may change.  Additional blood samples may 
be taken for safety assessments at times spe cified by [CONTACT_4618], provided the total volume taken 
during the study does not exceed 550 mL dur ing any period of 60 consecutive days.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 59To prepare for study participation, participants will be instructed on the information in the 
Lifestyle Considerations andConcomitant Therapy sections of the protocol.
8.1. Efficacy Assessments
Not applicable.
8.2. Safety Assessments
Planned time points for all safety assessments are provided in the Schedule of Activities .
Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety concerns.
8.2.1. Physical Examinations
A complete physical examination will include, at a minimum, head, ears, eyes, nose, 
throat/mouth, neck, skin, cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, lymphatic,
musculoskeletal, and neurological systems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_110251], and participant-reported symptoms.
Physical examinations may be conducted by a physician, trained physician's assistant, or
nurse practitioner as acceptable according to local regulation. 
8.2.2. Vital Signs
Supi[INVESTIGATOR_78235]’s arm supported at the level of the heart, and 
recorded to the nearest mm Hg after approximately  [ADDRESS_455936]. The same arm 
(preferably the dominant arm) will be used throughout the study. Participants should be 
instructed not to speak during measurements.  
When triplicate measurements are required (see Schedule of Activities ), they will be obtained 
approximately 3 minutes (±1 minute) apart; the average of the triplicate measurements on Day -1 will serve as each participant’s time-c ontrolled baseline value. The same properly 
sized and calibrated BP cuff will be used to measure BP each time.  The use of an automateddevice for measuring BP and pulse rate is acceptable; however, when done manually, pulse rate will be measured in the brachial/radial artery for at least 30 seconds.  When the timing of these measurements coincides with a blood co llection, BP and pulse rate should be obtained 
prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety data.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-[ADDRESS_455937] twelve (12)-Lead ECGs should be collected at times specified in the Schedule of
Activities section of this protocol using an ECG machine that automatically calculates the
heart rate and measures PR, QT, and QTc intervals and QRS complex. All scheduled ECGs should be performed after the participant has res ted quietly for at least [ADDRESS_455938] be performed prior to the meal/snack.
Triplicate 12-lead ECGs will be obtained approximately 3 minutes (±1 minute) apart; the 
average of the triplicate ECG measurements collec ted at each nominal time point on Day -1 
will serve as each participant’s time-controlled b aseline value. To ensure safety of the 
participants, a qualified individual at the inve stigator site will make comparisons to baseline 
measurements. Additional ECG monitoring will occur if a) the mean value from the triplicate measurements for any postdose QTcF interval is increased by ≥30 msec from the 
baseline andis >450 msec; or b) an absolute QTcF value is ≥[ADDRESS_455939] hourly until QTcF values from 2 successive ECGs fall below the threshold value that triggered the repeat measurement.
If a postdose QTcF interval remains ≥30 msec from the baseline andis >450 msec; or b) an 
absolute QTcF value is ≥500 msec for any scheduled ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator), or QTcF intervals get progressively longer, the participant should undergo continuous ECG monitoring.  A cardiologist should be consulted if QTcF intervals do not return to less than the criterion listed above after 8 hours of monitoring (or sooner, at the discretion of the investigator).
ECG data will be submitted to a blinded central reader for assessment.  The final ECG report 
from the central reader should be maintained in the participant’s source documentation and be the final interpretation of the ECG recording. 
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead
placement as contributing to the ECG abnormality.  It is important that leads be placed in the same positions each time in order to achieve precise ECG recordings. If a machine-read QTcF value is prolonged, as defined above, repeat measurements may not be necessary if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix [ADDRESS_455940] of clinical safety laborato ry tests to be performed and the 
Schedule of Activities for the timing and frequency.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-[ADDRESS_455941] any
clinically relevant changes occurring during the study in the AE section of the CRF. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by [CONTACT_364955]'s condition.
All laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_455942] dose of study intervention should be
repeated until the values return to normal or baseli ne or are no longer considered clinically 
significant by [CONTACT_10982].
If such values do not return to normal/baseline within a period of time judged reasonable by
[CONTACT_093], the etiology should be identified and the sponsor notified.
All protocol-required laboratory assessments, as defined in Appendix [ADDRESS_455943] be conducted 
in accordance with the laboratory manual and the Schedule of Activities .
If laboratory values from non-protocol-specified laboratory assessments performed at the 
institution’s local laboratory require a change in participant management or are consideredclinically significant by [CONTACT_093] (eg, SAE or AE or dose modification), then the results must be recorded in the CRF.
Participants may undergo random urine drug testing at the discretion of the investigator.  
Drug testing conducted prior to dosing must be negative for participants to receive investigational product (exception may be made for medically prescribed benzodiazepi[INVESTIGATOR_1651], see Section 5.2 ).
[IP_ADDRESS]. Fasting Fingerstick Blood Glucose (via Glucometer)
Investigators will monitor fasting fingerstick blood glucose (FSBG) using a glucometer at the
times specified in the Schedule of Activities . While the participant is confined to the CRU,
FSBG measurements should be taken each morning before breakfast.
FSBG readings will be maintained at the sites in source documents, and only the glucose
results from the laboratory will be reported in the study database. The sites may share the
FSBG readings with the sponsor for the purpose of dose-escalation decisions, but these datawill be stored in the sites’ source documents unless related to an AE as described in Section [IP_ADDRESS] below. 
If an FSBG result is ≤70 mg/dL , a second FSBG should be obtained to confirm the glucose 
value, in addition to a venous sample that will be sent to the clinical laboratory for confirmation. If the value from this second FSBG is also ≤70 mg/dL, the second value will 
be recorded as a hypoglycemic AE (see Section [IP_ADDRESS] ). FSBG will continue to be 
monitored until the glucose value returns to >70 mg/dL. Samples may be taken more frequently if deemed necessary by [CONTACT_093]. FSBG readings from a glucometer are permitted at any time if the investigator or participant notes symptoms of hypoglycemia.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Hypoglycemia Reporting
Hypoglycemia will be assessed and reported in several categories: severe hypoglycemia,
documented symptom atic hypoglycemia, asym ptomatic hypoglycemia, and probable
hypoglycemia.
Severe hypoglycemia : In order to be considered severe hypoglycemia allof the following
[ADDRESS_455944] be met:
1. The participant had 1 of the following:
•Blood glucose <50 mg/dL; or
•If blood glucose was not measured, the clinical manifestations were reversed by
[CONTACT_364956].
2. The participant required the assistance of another person to actively administer
carbohydrate, glucagon, or other resuscitative actions.
3. The participant exhibited at least 1 of the following neurological symptoms:
•Memory loss;
•Uncontrollable behavior;
•Irrational behavior;
•Unusual difficulty in awakening;
•Suspected seizure;
•Seizure;
•Loss of consciousness.
Documented symptomatic hypoglycemia : An event during which typi[INVESTIGATOR_364939] a measured glucose concentration ≤70 mg/dL.
Asymptomatic hypoglycemia : An event not accompanied by [CONTACT_11017][INVESTIGATOR_364940] a measured glucose concentration ≤70 mg/dL.
Probable symptomatic hypoglycemia : An event, during which typi[INVESTIGATOR_364941] a real time glucose determination, but werepresumably caused by a plasma glucose concentration ≤70 mg/dL. The clinical pi[INVESTIGATOR_364942], subcutaneous glucagon, or intravenousglucose.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 638.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or 
the participant's legally authorized representative).
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue and obtain adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE or that caused the participant to discontinue the
study intervention (see Section 7 ).
In addition, the investigator may be requested by [CONTACT_22835]-up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent,which is obtained before the participant’s par ticipation in the study (ie, before undergoing 
any study-related procedure and/or receiving investigational product), through and including a minimum of [ADDRESS_455945].
For participants who are screen failures, th e active collection period ends when screen failure 
status is determined.
Medical occurrences that begin before the start of study intervention but after obtaining 
informed consent will be recorded on the Medical History/Current Medical Conditions section of the case report form (CRF), not the AE section.
Follow-up by [CONTACT_74095] a level acceptable to the investigator, and[COMPANY_007] concurs with that assessment.
Investigators are not obligated to actively seek AE or SAE after conclusion of the study
participation. However, if the investigator l earns of any SAE, including a death, at any time
after a participant has been discharged from the study, and he/she considers the event to bereasonably related to the study intervention or study participation, the investigator must 
promptly notify the sponsor.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period are reported to [COMPANY_007] 
Safety on the CT SAE Report Form immediately and under no circumstance should this exceed 24 hours, as indicated in Appendix 3 . The investigator will submit any updated SAE 
data to the sponsor within 24 hours of it being available.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 64SAEs occurring in a participant after the active collection period has ended are reported to 
[COMPANY_007] Safety if the investigator becomes aware of them; at a minimum, all SAEs that the investigator believes have at least a reasonable  possibility of being related to investigational 
product must be reported to [COMPANY_007] Safety.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonser ious AEs and SAEs are recorded on the CRF.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open-ended and 
nonleading verbal questioning of the participant  is the preferred method to inquire about 
AE occurrences.
8.3.3. Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3 ).
In general, follow-up information will include a description of the event in sufficient detail to
allow for a complete medical assessment of the case and independent determination of possible causality.  Any information relevant to th e event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to [COMPANY_007] Safety. 
Further information on follow-up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by [CONTACT_364957].
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with country-specific regu latory requirements relating to safety 
reporting to the regulatory authority, institutional review boards (IRBs)/ethics committees 
(ECs), and investigators.
Investigator safety reports must be prepared  for suspected unexpected serious adverse
reactions (S[LOCATION_003]Rs) according to local regul atory requirements and sponsor policy and 
forwarded to investigators as necessary.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 65An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the investigator’s  brochure and will notify the IRB/EC, if 
appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the investigational product under study during pregnancy or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
Details of all pregnancies in female partners of male participants will be collected after the 
start of study intervention and until the last follow-up visit.
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 4 .
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.
[IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safety within 24 hours of the investigator’s awareness, using the CT SAE Report Form.  An exposure during breastfeeding report is not created when a [COMPANY_007]drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_4693], which may or may not lead to the occurrence of an AE.
An occupational exposure is repor ted to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated SAE.  Since the information does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file.
8.3.6. Medication Errors
Medication errors may result from the administration or consumption of the investigational 
product by [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -[ADDRESS_455946] u d y  m a y  occ ur i n cli nic al trial setti n gs, s u c h 
as me dica ti o n er r ors. 
S af et y E ve n t Rec or d e d o n t he C RF  Re p orte d o n t he C T S A E Re p ort 
F or m t o [COMPANY_007] S a fet y Wit hi n 2 4 
H o urs of A w are ness 
Me di cati o n err ors All (re gar dless of w h et h er 
ass oc iate d wit h a n A E) Onl y  if ass ociate d wit h a n S A E 
Me dicati o n err ors i ncl u de: 
Me d ica ti o n err o rs i n v ol vi n g par tici pa nt e x p os u re t o t he i n vest i ga ti o nal pr o d uct; 
P ote ntial m e di ca ti o n er r ors or uses o utsi de of w ha t is f oresee n i n t h e pr ot oc ol t hat d o 
or d o n ot i n v o lve t he st u d ypartici pa nt .
S uc h me dicati o n err ors occ urri n g t o a st u d y p arti ci p a nt are t o be ca p t ure d o n t he medica ti o n 
err o r pa ge of t he C R F, w hic h is a s pecific ve rsi o n of t he A E pa ge. 
I n t he e ve nt of a me dicati o n d osi n g err or, t he s p o ns o r s h o ul d be n oti fie d i m me dia te l y .
W he t her or n ot t he me d icati o n err or is acc om pa nie d b y  a n A E, as deter m i ne d b y  t he 
in ve sti g at o r, t he m e dica ti o n e rr or is rec or de d o n the me dicati o n err or pa ge o f t he C R F a n d, if 
a p plica bl e, a n y ass ociate d A E(s), seri o us a n d n o nser i o us , are rec or de d o n an A E pa ge of t he 
C R F. 
Me d icati o n err ors s h o ul d be re p ort e d t o P fizer Saf et y  wit hi n [ADDRESS_455947] o p pi n g l i mit  
wi t hi n a 2 4 -h o ur ti m e 
peri o d will be c o nsi dere d a n o ver d ose .
I n t he e ve nt of a n o ver d os e, t he i n ves ti gat or /treati n g p h ys icia n s h o ul d: 
1. C o ntact t he me dical m o ni t or i m me diatel y .
2. C l osel y  m o nit or t he p ar ti ci pa n t f or a n y AEs/ S A Es a n d la b orat or y  a b n or maliti es u ntil 
P F - 0 7 0 8 1 5 3 2 ca n n o l o n ger be detecte d s ys te micall y  (at least 5d a y s) .
3. D oc u me nt t he q u a ntit y of t he e xcess d ose as w e ll as t he d urati o n of t he o ve r d o se i n 
the C R F .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455948] u d y i nter ve nti o n if re q ueste d b y  t he medical mo nit o r ( deter m i ne d o n a case -b y -case 
basis). 
Decisi o ns re gar di ng d o se i nterr u pti o ns or m o dific ati o n s wil l be m a de b y th e i n vesti g at or i n 
co ns ultati o n wit h the me di ca l m o nit or base d o n t he cli nical e val ua ti o n of t he p art ici pa nt. 
8. 5. P h ar m a c oki netics 
8. 5. 1. Pl a sm a f or An a l ysis of P F - [ADDRESS_455949] as ma , w ill be 
c o lle cte d i nt o a p p r o priatel y la bele d t u bes c o ntai ni n g d i p o tassi u m et h y le ne dia mi netetraacetic 
aci d ( K 2E D T A )f or meas ure me nt of plas ma c o n ce ntrati o ns o f P F -[ADDRESS_455950] ual 
da te a n d ti me ( 2 4- h o ur cl oc k ti m e) of eac h sa m p le will be re c or d e d. 
T he act ual ti mes ma y  c h a n ge, b ut t he n u m ber of sa m p le s wil l re m ai n t he s a me. A n y  c ha n g es 
i n t he ti mi n g or a d di ti o n of ti me p oi nts f or a n y pla n ne d st u d y  as sess me nts m u st be 
d oc u m e nte d a n d a p pr o v e d b y  t he rele va nt st u d y  t ea m me m ber a n d the n ar c hi ve d i n the 
s p o ns or a n d site st u d y  files b ut will n ot c o nst it ut e a pr o t oc ol a me n d me n t. 
Sa m ples w ill be use d t o eval uate t he P K of P F -0 7 0 8 1 5 3 2. Sa m ples c ollecte d f or 
meas ure me nt of plas ma c o nce ntrati o ns of P F- 0 7 0 8 1 5 3 2 will be a nal yz e d usi n g a vali d ate d 
a nal yt ical m et h o d i n c o m pli a nc e wit h a p plica ble sta n dar d o perat i n g pr oce d ures (S O Ps). 
 
 
 
 
 
 
T he P K sa m p les m us t be pr oc es se d a n d s hi p pe d as i n dicat e d i n t he i nstr ucti o ns p r o vi de d t o 
t he i n vesti gat or site t o m ai ntai n sa m ple inte grit y. A n y  de viati o ns fr o m t he P K sa m p le 
ha n dl i n g pr oce d ure (e g , sa m ple c ollecti o n a n d pr o cessi n g s te ps, i nteri m st ora ge or s hi p pi n g
c o n di ti o ns), i ncl u di n g a n y  acti o ns ta ke n, m ust be d oc u me nte d a n d r e p or te dt o t he s p o ns or.  
O n a case -b y -case basis, t h es p o ns o r ma y  deci de as t o w het her sa m ple i nte grit y has bee n 
c o m pr o m ise d. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455951] u d y has bee n u n bli n de d.
 
 
 
 
8. 5. 3. U ri n ef or An al ysis of P F- 0 7 0 8 1 5 3 2 
Uri ne will b e c oll ecte d at t imes s pecifie d i n t he Sc he d ule o f Acti vities .
Pri or t o d osi n g o n D ay [ADDRESS_455952] c o m plete a f o rce d v oi d wit h a n
ali q u ot (a p pr o xi ma tel y  1 0 m L )fr o m t hi s uri ne ( uri ne bla n k) la bel e d an d st ore d 
fr oze n f or meas ure me nt of dr u g c o n ce n trati o n s, per detai le d i n st r uc ti o ns offe re d i n a 
la b orat or y ma n u al pri o rt o t he start of t he st u d y. 
F oll o wi n g d osi n g o n D a ys  S pecifie d i n t he Sc he d ule of Acti viti es,ea c h v oi d p os t 
d ose will be c ollecte d an d sa ve d i n a c o ntai ner a n d st ore d i n re fri gera t e d c o n dit i o ns 
(ie, 2- 8° C) f o rt h e d u rat i o n of t he c ollecti o n i nter val s, as s pec ifie d i n t he Sc he d ule of 
Acti vities .
J ust pri or t o t he first c ollecti o n i nter val, partici pa nts will c o m plete a f orce d v oi d 
a n d t he uri ne will b e disc ar de d ;
At t h e e n d of eac h c o llecti o n inter val, partic ipa nt sm ust c o m plete a f o rce d v oi d 
wi t h t his c o m pl ete v oi d i nc l u de d as p art o f t he i nter val c ollecti o n; 
The ur i ne c o ntai ner will be mi xe d t h or o u g hl y  a n d t otal v ol u me pl us w ei g ht of t he 
uri ne c ollecte d d uri n g t he i nte r v al rec or de d; 
A n ali q u o t(a p pr o xi matel y 2 0 m L )will be la be le d a n d st o re d fr oze n f or t he 
p ote ntial me as ure me nt of dr ug conce ntrati o ns 
per detaile d i nstr ucti o ns offere d i n a la b orat or y  ma n ual pri or t o t he start 
of t he s t u d y ; a n d t h ere mai ni n guri ne discar de d. 
De tails re gar di n g t he pr o ce ssi n g, st o ra ge a n d s hi p pi n g of t he sa m ple s wil l be pr o vi de d i n t he 
la b ma n ual. T he s hi p me nt a d dr ess a n d assa y  la b c o ntact i nf or mati o n will b e pr o vi de d t o t he 
i n vesti gat or site p ri or t o i ni tiati o n of t he st u d y .  T he uri ne sa m ples m ust be pr ocess e d as 
i n dic ate d t o ma i ntai n sa m ple i nte gri t y . A n y d e viat i o ns fr o m t he uri ne sa m p le pr oces si n g 
ste ps gi ve n i n t he pr ot oc ol or la b ma n ual, i ncl u di n g a n y acti o ns ta ke n, m ust be d oc u me nte d 
a n d re p ort e d to t he s p o ns or. O n a case -b y -case ba sis, t he s p o ns or ma y ma ke a det er mi nati o n 
as t o w h et her sa m ple i nte grit yhas bee nc o m pr o mise d. A n y s a m ple dee me d o utsi de o f 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -[ADDRESS_455953] a blis he d sta bilit y, or of q uesti o na ble i nte g rit y, will be c o nsi dere d a pr ot oc ol d evia ti o n.  
Sa m ples f o ra nal ys is of P F - 0 7 0 8 1 5 3 2 P K wil lbe a nal y ze d usi n g va li d ate d a nal y tical met h o ds 
i n c o m p lia nce wit h Pfi zer sta n dar d o perati n g p r o ced ures .
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455954] be p la ce do n a sta bl e, f lat s ur face. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -[ADDRESS_455955] u d y  site as liste d i n t he Sc he d ule of 
Acti vities u n de r t h e f oll o w in g c on diti o ns: 
After v oi d of uri ne ;
After r e m o val of s h oes, b u l k y l a y ers of cl ot hi n g, an d jac kets sot ha to nl y  li g ht 
cl ot hi n g re mai ns; 
W h ile re mai ni n g still d uri ng meas ur e m e n t. 
D uri n g a d mi ssi o n t o t h e C R U, b o d y  we i g ht will be me as ure d at t h e ti me p oi nt slis te d i n t he 
Sc he d u le of Acti vities . Meas ure m e nt will be ta ke n u n der t he f oll o wi n g c o n dit ions: 
I n t he m or ni n g, pri or t o ea ti n g a n d dri n ki n g a n d pri or t o d ose a d mi n istrati o n, w here 
a p plica b le ;
After t he par tici pa nt has bee n as ke d t o v o i d; 
W hile we ari n g o nl y a h os p ital g o wn a n d n o s h oe s; 
W h ile re mai ni n g still d uri n g m ea s ure m e nt . 
 
 
  
 
 
 
 
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 7 2   
 
 
 
 
  
 
 
 
 
 
 
8. 9. He a lt h Ec o n o mics 
Healt h e c o n o mics / m e dic al res o ur ce util iz ati o n a n d healt h ec o n o mi cs pa ra m eter s are n ot 
e val uate d i n t his s tu d y .
9. S T A TI S TI CA L C O N SI D E R A TI O N S
De ta ile d me t h o d ol o g y f or s u m mar y a n d stati stical a na l y s e s of t he data c ollecte d i n t his st u d y  
iso utli ne d here a n d f urt her detaile d i n a sta tis tical a nal ysi s pla n ( S A P), w hic h wil l b e
mai nta i ne d b y  t he s p o ns or.  T he S A P ma y m o dif y what is o utli ne d i n t he pr o t o c ol w he re 
a p pr o p riat e; ho we v er, a n y  ma j or m o difi cati o ns of t he pri mar y  e n d p oi n t defi niti o ns or t heir 
a nal ys es will als o be ref lect e d i n a p r ot oc o l a me n d me nt. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI C CI 
P F -[ADDRESS_455956] ud y .
9. 2. S a m ple Size Det er mi n ati o n 
P ar tA a n d P art C (if c o n d u ct e d), partici pa nts wit h T 2 D M : asa m pl esize of u p t o 
a p p r o xi matel y 1 0 partici pa nt sper co h ort (8 ac ti ve, 2 p lace b o) h a s be e n sel ecte d t o mi ni mize 
e x p os ure t o h u ma ns t oa ne w c h e m ic al e nti t y  w hile all o w i n g a de q uate c ha r a ct eriz ati o n of 
safet y a n d t olera bili t y , P K ,  a t eac h d ose le vel i n t his p o p ulati o n .  
P a rt B(if c o n d ucte d), o bese pa rtici pa nt s: a s a m pl e s ize of u p t o a p p r o xi ma tel y 
1 5 partici pa nt sper c o h o rt ( 1 2 acti ve, 3 plac eb o) has bee n s el ect ed t o m i n i mi ze e x p o s u re of 
h u ma ns t o a ne w c he mical e nt it y  w h ile all o wi n g a de q ua te c haracterizati o n of safet y a n d 
t olera bi lit y , P K ,  at eac h d ose le v el i n t hi s p o p ulat i o n . 
 
9. 3. P o p ul at i o ns f or A n al ysis 
F or p ur p ose s of a nal y ses the f oll o wi n g p o p ul ati o ns are de fi ne d: 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI C CI 
C CI 
P F -[ADDRESS_455957] u d y  t o e v al uate t he safet yof 
partici pa nts. A n y cli n ic al la b orat or y, E C G , B P, a n d p ul se rate a b n o r ma lities of p ote ntia l 
cli n ical c o ncer n wil l b e d escri be d.  Safet y dat a wil l be pres ente d i n ta b ular a n d/ or gra phic al 
f o r ma t a n d s u m marize d descri pti vel y, w here a p pr o p ri ate. 
Me d ical hist or y a n d p h ysi cal e xa mi nat io n i nf or mati o n, as a p plica ble, collecte d d ur i n g t he 
c o urse of t he st u d y will be c o nsi de re d source data a n d wi ll n o tbe re quire d to be re p ort e d, 
u nles s o t he r wis e n ot e d.   H o w e v er, a n y u nt o war d fi n di n gs i de ntifie d o n p h ys ica l a n d/ or 
ne ur ol o gica l ex a mi nati o ns c o n ducte d d ur i n g t h e acti ve c o ll ecti o n peri o d w ill be ca pt ure d as 
A Es, if t h ose fi n di n g s m eet t he defi ni ti o n of a n AE. 
Dat a c o llecte d at s cree ni n gt hat a re u se d for i nc l u si o n/e xcl us io n criteria, s uc h as la b ora t o r y  
data ( u nless n ote d bel o w), E C G s, a n d vita l si g ns, wil l be c o ns i dere d s o urce data, a n d will n o t 
be re q uire d t o be re p orte d, u nl ess ot her wise n ote d.  De m o g ra p hic data c ol l e cte d at sc ree ni n g 
wi ll be re p or te d. I n a d dit i o n, sele cte d scree ni n g la b orat or y  data :  
 T B A  will be re p orte d .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 7 5 9. 4. 2. 1. E lec tr oc ar di o gr a m A n al yses 
C ha n ges fr o m b as el i ne f or t h e E C G par ameters Q T i nter va l, heart rate , Q Tc F inte r val, P R
i n ter val , a n d Q R S i nter v al will be su m mari ze d by [CONTACT_364958] a n d ti me. 
T he n u m ber ( % )of partici pa nts wit h ma xi m u m p o st d ose Q Tc F val u es a n d ma xi m u m 
i ncreases fr o m baseli ne i n t he f oll o wi n g cate g ories w ill be ta b ulate d b y  t rea tme nt: 
Safet y Q Tc F Asse ss me nt 
Pr o l o n gati o n Mil d Mo derate Severe 
A b s ol ute va l u e ( m sec) 4 5 0 -4 8 0 4 8 0 -5 0 0 5 0 0 
I n crease fr o m ba se li ne 
i n Q Tc F ( msec) 3 0 -6 0 6 0 
I n a d diti o n, t he n u m ber of partici p a nts wit h c orrecte d a n d u nc o rre cte d QT v al ues > 5 00msec 
wi ll be s u m marize d. 
At t he n o m i nal t ime p oi nts, t he mea n of t he tri p lica te m eas u re me n ts wi ll be use d t o re prese nt 
a si n gle o bser va ti o n at t hat ti me p oi nt.  I f a n y  of t he 3 i n di vi d ual E C G traci n gs has aQ Tc F 
va l ue > [ADDRESS_455958] icates i s n o t > 5 0 0 msec, t he d ata fr o m t he 
partici pa nt ’s in di vi d ual tra ci n g wil l be de scr i be d i n asafet y secti o n of t he st ud y  re p ort i n
or der t o place t he > 5 0 0 msec val ue i n a p pr o pri ate cli nical c o nte xt.  H o w e ver, v al ues fr o m 
i n di vi d u al t rac i n gs wit hi n t ri pli cate mea s ure me nts t hat are > 5 0 0 m sec wi ll n ot be i ncl u de d i n 
t he ca te g o rica l a n al y sis u nless the a vera ge fr o m t he tri pli cate meas ur e m e n ts is als o 
> [ADDRESS_455959] ace b o sa m ples will not be r o uti nel y  
a nal yz e d. A d diti o nal de tail o n P K para me te rdefi niti o n for ti trat ed a n d n o n -ti trate dc o h orts 
will be pr o vi de d i n t he S A P. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455960] as m a P K P ar a m et ers f or P F -0 8 7 0 8 1 5 3 2 
P a r a m eter Da y 1 ( D 1 )or 
Ste a d y S t ate 
(S S )Def initi o n M e t h o d of Deter m i n ati o n 
Cma x D 1 & S S  M a xi m u m p la s m a c o nce ntrat i o n 
o bser ve d fr o m ti me zer o t o 
2 4 h o ur sO bser ve d directl y fr o m data 
Tma x D 1 & S S Ti m e f or C ma x Obser ve d directl y fr o m  da ta as ti me of 
first occ urre nc e
Cma x ( d n) D 1 & S S Cma x nor m aliz ed t o a 1m g d ose Cma x / D ose 
A U C 2 4 D 1 & S S  A re a u n der t he p las ma 
c o nce ntrati o n -ti m e pr ofile fr o m 
ti m e zer o t o ti me 2 4 h o urs Li near/ L o g tra pez oi dal met h o d 
A U C 2 4 ( d n ) D 1 & S S A U C 2 4 n or m al ize d t o a 1 m g 
d ose A U C 2 4 / D ose 
 
 
 
 
  
 
t½aS S T er m i na lhal f- life L o g e( 2)/ k el , w here k el is t he ter mi nal 
p hase rate co nsta nt c al c u late d b y a 
li near re gr essi o n of t he l o g -li n ear 
c o nce ntra ti o n -ti m e c ur ve.  Onl y t h ose 
da ta p oi nt s j u d ge d t o des cri be t he 
ter mi nal l o g -li ne ar decli ne wil l be 
use di n t he re gressi o n. 
a. If data per mi t. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -[ADDRESS_455961] at e ( S S) Defi niti o n M e t h o d of Deter m i n a ti o n 
Ae [ADDRESS_455962] u g 
rec o vere d i n uri n e o ver 2 4 h o urs S u m of [ uri ne c o nce ntrati o n * sa m ple 
v o l u m ea]f or eac h c ol le cti o n o ver t he 
d o si n g i nter val 
Ae 2 4 % S S Perce nt of d ose rec o vere d i n uri ne 
as u nc ha n ge d dr u g 1 0 0 * Ae 2 4 / D ose 
C L r S S Re nal cl ea ra nce Ae 2 4 / A U C 2 4 
a. sa m ple v ol u m e =( Ur i n e we i g h t i n g /1. 0 2 0) ,w h ere 1. 0 2 0 g/ mL is t he a p pr o xi mate s pecific gr a v it y of 
uri ne .
T h e plas m a a n d uri ne P K para meters will be s u m mariz ed descri pti vel y b y act ual d ose 
recei ve d (a n d treat me nt, if a p pl ic able) , i n a cc o r d a nce wit h [COMPANY_007] sta n dar d s. Ea c h C o h ort 
will be c o nsi dere d as a se p ar ate treat me n t.If da ta p er mi t, d ose - n or malize d ar ea u n der t h e 
plas ma c o n ce ntrati o n t ime pr ofile fr o m ti me 0 to 2 4 hr [ A U C2 4 ( d n) ]a n d d ose- n or malize d 
Cma x [ C ma x ( d n) ] w il lbe pl otte d a ga i nst d ose ( p ote ntiall y  o n a l o g arit h mic scale de pe n di n g o n 
the e xte n t of t h e d ose ra n g e) (a n d tr eat me n t, if a p plica b le ), a n d wil l i ncl u de i n di vi d ual 
partic ipa nt val ues a n d t he ge o metr ic mea n sf or eac hd ose (a n d treat me nt, if a p pli ca ble) .
T h ese pl ots wil l be u se d t o hel p u n dersta n d t he r elati o ns hi p bet wee n t he P K p ara m eter s a n d 
dose (a n dtr eat me nt, if a p pl ica ble ).
Plas m a c o nce n trat i o n s of P F - [ADDRESS_455963] e d a n d descri pti vel ys u m marize db y  
n o mi nal P K s a m pli n g ti me a n d d os e(a n d trea t m ent, if a p p lic a b le) .I n di vi d ual partici pa nt a n d
me dia n pr ofiles of t he plas ma c o nce nt rati o n-t i me data will be pl ot te d b y  d o se (a n d tr ea tme n t, 
if a p plica ble ) u si n g act ual an d n o mi nal ti mes, res pec ti v el y. Media n pr o files wi ll be 
prese nte d o n b ot h li near -li near a n d l o g-l i n ear scales. 
 
 
 
 
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 7 8  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
P F -[ADDRESS_455964] u d y f o rt he p ur p ose of safet y assess me nt a n d facilitati n g 
d ose- escalati o n decis i o ns.   I n ad diti o n, t hese re vie ws ma y  f acil itate P K  m o del in g a n d/ or 
s u p p orti n g cli nical de vel o p me n t.
9. 5. 1. D at a M o nit or i n gC o m mit tee 
This st u d y wi ll n ot use a dat a m o nit ori n g c o m mi ttee (D M C ). 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 8010. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations10.1.1. Regulatory and Ethical ConsiderationsThis study will be conducted in accordance with the protocol and with the following:
•Consensus ethical principles derived from international guidelines including the
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines;
•Applicable International Council for Harmonisation (ICH) Good Clinical Practice 
(GCP) guidelines;
•Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, investigator’s brochure (IB), and other relevant
documents (eg, advertisements) must be reviewed and approved by [CONTACT_22842]/EC by [CONTACT_22843]/ECbefore the study is initiated.
Any amendments to the protocol will requ ire IRB/EC approval before implementation of
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.
The investigator will be responsible for the following:
•Providing written summaries of the status of the study to the IRB/EC annually or
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/EC;
•Notifying the IRB/EC of SAEs or other signif icant safety findings as required by 
[CONTACT_1744]/EC procedures;
•Providing oversight of the conduct of t he study at the site and adherence to
requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB/EC, 
European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_364959], or if the investigator is aware of any new information that might influence the evaluation of  the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-[ADDRESS_455965], and 
of any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
10.1.2. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions regarding the study.
Participants must be informed that their participation is voluntary. Participants or their 
legally authorized representative will be required to sign a statement of informed consent thatmeets the requirements of [ADDRESS_455966] (HIPAA) requirements, where applicable, and the IRB/EC or study center.
The investigator must ensure that each study participant is fully informed about the nature 
and objectives of the study, the sharing of da ta related to the study, and possible risks 
associated with participation, including the risks associated with the processing of the
participant’s personal data. 
The participant must be informed that his/her personal study-related data will be used by [CONTACT_140261]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/ her medical records may be examined by [CONTACT_11000], by[CONTACT_6667]/EC members, and by [CONTACT_6668].
The investigator further must ensure that each study  participant is fully informed about his or 
her right to access and correct his or her per sonal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained
before the participant was enrolled in the study and the date the written consent was obtained.The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study.
A copy of the ICD(s) must be provided to the participant or the participant’s legally 
authorized representative.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -[ADDRESS_455967] i o n of part ici pa nt data. 
Pa rtici p a n ts ’pers o n al d ata will be st ore d at t he s t u d y  site i n e ncr y pte d e lectr o nic a n d/ or pa per 
f o rm a n d wi ll be pass w or d p r otecte dor s e c ure d i n a l oc ke d r o o m t o e ns ure t hat o nl y  
a ut h orize d st u d y sta ff ha ve a cc ess.  T he st ud y  si te w ill i m p le me n t a p pr o p ri ate tec h n ic al a n d 
or ga n izati o nal meas ures t o e ns ure t hat t he pers o nal data ca n be rec o vere d i n t h ee ve nt o f
dis ast er.  I n t he e ve nt of a pote ntial pe rs o nal d a ta breac h ,t he st u d y  site s hall be r es p o nsi ble 
f or d eter mi ni n g w he ther aper s o n al d ata b reac h has i n f act o cc urre d a n d, if s o, pr o vi di n g 
breac h n otificati o ns as re q uire d b y la w. 
T o pr otect t h e ri ghts a n d f re e d o ms of nat ur al pers o ns wi t h re gar d to t h e p roce ssi n g of 
pe rs o nal data, partici pa nts wil l b e assi g ne da si n gl e, par tic i p a nt -s pe cifi cn u m erical c o d e. 
A n y  p ar tici pa nt rec or ds or data sets t hat are tra nsferre d t o t he s p o ns o r will c o ntai n t he 
n u m erica lc o de; part ici pa nt n a mes wil ln ot b e tra nsf err ed. A ll ot her i de nt ifia bl e data 
tra nsferre d t o t h e s p o ns or w ill be i de ntif ie d b y t hi s s in gl e, pa rtici pa n t-s pec ific c o de. T he 
st u dy site will mai ntai n a c o nfi de ntial list of partic ipa nt s w h o partici p ate d i n t he s tu d y, 
li nki n g eac h partic ipa nt ’s n u meric al code to h is or her act ual i de ntit y . I n case of da ta 
tra nsfer ,t he s p o ns or will pr ote ct the co nfi de ntiali t y of parti ci pa nt s’ p ers o nal data c o nsiste nt 
wit h t he cli nical st u d y  a gree me nt a n d a p plica ble p ri va cy la ws. 
[ADDRESS_455968] u di es o n w w w.c li nicaltri als. g o v ( Cli nica l Trials. g o v), t he E ur o pea n Cli nical Tri als 
Data base ( E u d ra C T), a n d/ or w w w. pfizer .c o m, a n d ot her pu bli c re gi stri es i n ac c o r d ance wit h 
ap plica ble l ocal la ws/re g ula ti o ns .  I n a d d it i o n, Pf izer re p o rt s st u d y res ult s o utsi de of t he 
re q u ir eme nts o f l o cal la ws /re g ulati o ns p urs ua nt t o its sta n dar d opera ti n g pr oce d ures ( S O Ps). 
I n a ll cases, st u d y  res ults are r ep ort e d b y  P fiz er ina n obje cti ve, a cc urate, bala nce d, a n d 
c o m plete ma n ner a n d ar e re p or te d r egar dl ess of t h e o ut c o me of t h e st u d y  or t h ec o u ntr y i n 
w hic h t he s t u d y  was c o n d ucte d. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 83www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007]-sponsored
interventional studies (conducted in patients) that evaluate the safety and/or efficacy of a product, regardless of the geographical location in which the study is conducted.  US Basic Results are generally submitted for posting within 1 year of the primary completion date (PCD) for studies in adult populations or within [ADDRESS_455969]
[COMPANY_007] posts European Union (EU) Basic Results on EudraCT for all [COMPANY_007]-sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts public disclosure synopses (CSR synopses in which any data that could be used 
to identify individual participants ha ve been removed) on www.pfizer.com for
[COMPANY_007]-sponsored interventional studies at the same time the US Basic Results document is posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy 0070, the proactive publication of clinical 
data to the European Medicines Agency (EMA) website.  Clinical data, under Phase 1 of thispolicy, includes clinical overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this policy, includes the publishing of individual participant data.Policy 0070 applies to new marketing authorization applications submitted via thecentralized procedure since 01 January 2015 and applications for line extensions and for new indications submitted via the centralized procedure since 01 July 2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient-level data or full CSRs for the purposes
of “bona-fide scientific research” that contribute to the scientific understanding of thedisease, target, or compound class. [COMPANY_007] wi ll make available data from these trials 
[ADDRESS_455970] personally identifiable information redacted.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-[ADDRESS_455971], including individualsrequesting access for commercial/competitive or legal purposes.
10.1.5. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_364960].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access by [CONTACT_20011].
The investigator must permit study-related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide dir ect access to source data documents.  This 
verification may also occur after study completi on. It is important that the investigator(s) 
and their relevant personnel are available duri ng the monitoring visits and possible audits or
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy (eg, risk-based initiatives in operations and quality 
such as risk management and mitigation str ategies and analytical risk-based monitoring),
methods, responsibilities, and requirements, includin g handling of noncompliance issues and 
monitoring techniques (central, remote, or on-site monitoring), are provided in themonitoring plan.
The sponsor or designee is responsible for the data management of this study, including
quality checking of the data.
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_1747] a re accurate, complete, and verifiable from source 
documents; that the safety and rights of participan ts are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study must
be retained by [CONTACT_1732] [ADDRESS_455972] ensure that the records continue to be stored securely for as long as they are 
maintained.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 85When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_306891].
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the stud y. Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allowthe sponsor or its agent, whenever feasible, to be present during the inspection. The investigator site and investigator will promptly re solve any discrepancies that are identified 
between the study data and the participant's me dical records. The investigator will promptly 
provide copi[INVESTIGATOR_19946].  Before response submission to the regulatory authorities, the investigator will provide the sponsor or its agents with an opportunity to review and c omment on responses to any such findings.
10.1.6. Source Documents
Source documents provide evidence for the exis tence of the participant and substantiate the 
integrity of the data collected.  Source documents are filed at the investigator site.
Data reported on the CRF or entered in the ele ctronic CRF (eCRF) that are transcribed from
source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.
Definition of what constitutes source data can be found in the investigator site file.10.1.7. Study and Site Closure
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed uponstudy completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time upon notification to the contract
research organization (CRO) if requested to do so by [CONTACT_22846]/EC or if such 
termination is required to protect the health of study participants.
Reasons for the early closure of a study site by [CONTACT_19711]:
•Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
•Inadequate recruitment of participants by [CONTACT_093];
•Discontinuation of further study intervention development.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-[ADDRESS_455973] will control as to termination rights.
10.1.8. Publication Policy
The results of this study may be published or presented at scientific meetings by [CONTACT_364961] 1 year after end of the study (orstudy termination), whichever comes first.
The investigator agrees to refer to the pri mary publication in any subsequent publications 
such as secondary manuscripts, and submits all manuscripts or abstracts to the sponsor30 days before submission. This allows the s ponsor to protect proprietary information and to
provide comments and the investigator will, on request, remove any previously undisclosed confidential information before disclosure, ex cept for any study- or [COMPANY_007]-intervention 
related information necessary for the appropr iate scientific presentation or understanding of 
the study results.
For all publications relating to the study, the inve stigator will comply with recognized ethical 
standards concerning publications and authorship, including those established by [CONTACT_4717].
The sponsor will comply with the requirements for publication of the overall study results 
covering all investigator sites.  In accordance w ith standard editorial and ethical practice, the
sponsor will support publication of multicenter studies only in their entirety and not as individual site data.  In this case, a coordinating investigator [INVESTIGATOR_364943].
Authorship of publications for the overall study results will be determined by [CONTACT_364962]. 
If publication is addressed in the clinical study agreement, the publication policy set out in
this section will not apply.
10.1.9. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study is documented in the study contact [CONTACT_22848] (SToD) system.  
To facilitate access to appropriately qualif ied medical personnel on study-related medical 
questions or problems, participants are provided with a contact [CONTACT_1137].  The contact [CONTACT_364963], at a minimum, protocol and investiga tional product identifier s, participant numbers,
contact [CONTACT_22850], a nd contact [CONTACT_4664] a contact [CONTACT_74072] a medical question or problem originating from another healthcare professional not involved in the 
participant’s participation in the study.  The contact [CONTACT_364964] 090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 87staff if they are seeking advice on medical questions or problems; however, it should be used 
only in the event that the established commun ication pathways between the investigator site 
and the study team are not available.  It is th erefore intended to augment, but not replace, the 
established communication pathways between the investigator site and the study team for
advice on medical questions or problems that may arise during the study.  For sites other than
a [COMPANY_007] CRU, the contact [CONTACT_22853], and if a participant calls that number, he or she will be directed back to th e investigator site.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 8 8 1 0. 2. A p pe n d i x 2: Cli ni c al L a b or at or y Te sts 
T h e f oll o wi n g safet y la borat o r y  tests wi llbe perf or me d a tti mes d ef i ne d i n t he Sc he d ule of 
Act i vities .  A d diti o nal l a b orat or y re sults m a y be r e p o rte d o n t hese sa m p les a sa res ult of t he 
met h o d of a n al ys is or t he t y pe of a nal yz er use d b y  t h e cli nica l l ab orat or y ; or as deri ve d fr o m 
calc ul ate dval u es .  T hese a d d iti o nal tests w o ul d n ot re q uire a d diti o nal c ollecti o n of bl o o d .  
U nsc he d ul ed cl i nica l la b or at or y m eas ure me nts m a y  b e o bta i n ed a ta n y ti me d uri n g the s t u d y  
t o ass ess a n y p ercei ve d safe t y c o ncer ns .
Inves ti gat ors m ust d oc u me nt t he ir re v ie w of eac h la b orat or y  s afet y re p ort .
T a ble [ADDRESS_455974] r y / Ot her Ur in al ys is At s pec ifie d ti mes 
H e m o g l o bi n 
He mat ocri t
R B C c o u n t
M C V 
M C H 
MC H C 
Platelet co u nt 
W B C c o unt 
T otal ne ut r o p hil s ( A bs) 
E osi n o p hi ls ( A bs) 
M o n oc yte s (A bs) 
Bas o p h ils ( A bs) 
L y m p h o cytes ( A bs) B U N/ Urea 
Ser u m Creati ni ne a
Pl as m aGl uc ose (f as ti ng) 
Ca lc i u m 
S o di u m
Pota ss iu m 
C hl o ri de 
T o tal C O 2( bicar b o n ate) 
A S T
AL T 
T otal bi li r u bi n
Dire ct bili ru bi n 
I n di rect bilir u bi n 
Al kali ne p h os p hat as e
Ur ic ac i d 
Al b u mi n 
T otal Bile Aci ds ( T B A) p H 
Gl uc os e ( q ual) 
Pr otei n ( q u al) 
Bl o o d ( q ual) 
Ket o nes 
Nit rites 
Le u k oc y te est erase 
Ur o b ili n o ge n 
Uri ne bi lir u bi n 
Mi cr osc o p y bAt sc re e n i n g o n l y: 
F S H c
He pa titis B s urfac e a nti ge n 
( H bs A g) 
He pat itis C ( H C V) 
a nti b od y 
He p B c o re a nti b o d y 
( H bc A b) 
H u ma n i m m u n o defici e n c y 
vi r u s( H I V) 
At ti mes s pecifie d i n t he 
Sc h e d ul eof Act i vit ie s:
Uri ne dr u g scree ni n g e
Ab bre vi ati o ns: A bs = abs ol ut e; A L T = a la ni ne a mi n o tra ns ferase; A S T = as p artate a mi n o tr a nsferase ; 
- h C G = b eta -h u ma n c h ori o n ic g o na d otr o pi n; B U N = bl o o d urea ni tr o ge n; C O 2 = car b o n di o xi de ;
F S H =f o lli cl e -sti m ulati n g h o r m o ne ; M C H = mea n c o r p usc ular he m o gl o b i n;  M C H C = mea n c or p u sc ular 
he m o g l o bi n c o nce ntrati o n ; M C V = mea n c or p usc ular v ol u me; q ual = q ua lita ti v e; R B C = re d bl o o d cell; 
W B C =w h ite bl o o d cell .
a. Gl o m er ular Filtrati o n Rate ( G F R) wil l be calc ul ate d usi n g t he m o dificati o n of diet i n re nal disease 
(M D R D ) e q uati o n :
G F R ( ml/ m i n/ 1. 7 3 m 2) = 17 5 x s ta n dar di ze d Ser u m Creati ni n e- 1. 1 5 4 x age -0. 2 0 3 x 1. 2 1 2 
[i f bl ac k] x 0. 7 4 2 [if fe ma le] .
b. O nl y if u ri ne di pstic k is p o si ti ve f o rbl o o d, pr otei n, nitri tes ,or le u k o c y te ester ase. 
c. F or c o nfir mati o n of p o st me n o pa u sal stat us in fe male par ti ci pa nts o nl y. 
 
e. T he mi ni m u m r e q uire me nt f or d r u g scree n i n g i ncl u d es c oca i ne, tetr ah y dr o ca n n a bi n ol ( T H C), 
o pi[INVESTIGATOR_858]/ o pi o ids, be n z o d iaze pi [INVESTIGATOR_1651], a n da m pheta mi nes ( o t hers a re site a n d st ud y  s pe cific). 
Refl ex testi n g ma y be c o n d ucte d at i n vesti gat or di screti o n ; s uc h tes ts ma y  i ncl u de 
P T /I N R /partial t hr o m b o plasti n t i m e ( P T T), m y o gl obi n, c rea ti ne ki nase .0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
P F -[ADDRESS_455975] s as s pecifie d i n t h e Sche d ul e of A cti vitie s.
All a vaila ble r es ults of t h e safet yla b orat or y  tests liste d i n t he prece di n g ta ble will be 
re vie w e d as part of d ose escalati o n.  N ot e that re vie w o ft he f oll o wi n g la b orat or y  data is n ot 
re q uire d pri or t o d ose es ca lati o n or pr o gre ssi o n t o t he ne xt c o h ort /s tu d y  pa rt ; r es ults w ill be 
re vie we das t h e y  bec o me a v ail a ble. 
  
 T B A .
La b orat or y/a nal yt e res ults t hat c o ul d u n bl i n d t he st u d y   will n ot be 
re p or te d to i n ves ti gat or sites or ot her bli n de d pers o n n el u ntil t h e st u d y has be en u n bli n d e d ;
see a ls o Secti o n 9. 5 .
 
 
 
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 9010.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
10.3.1. Definition of AE
AE Definition
•An AE is any untoward medical occurre nce in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or not 
considered related to the study intervention.
•NOTE: An AE can therefore be any unfavora ble and unintended sign (including an
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
Events Meeting the AE Definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis)
or other safety assessments (eg, ECG, ra diological scans, vital sign measurements), 
including those that worsen from baseline,  considered clinically significant in the
medical and scientific judgment of the investigator (ie, not related to progression of underlying disease).
•Exacerbation of a chronic or intermittent preexisting condition including either an
increase in frequency and/or intensity of the condition.
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as
an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdos es should be reported regardless of 
sequelae.
Events NOT Meeting the AE Definition
•Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with th e underlying disease, unless judged by [CONTACT_11009]’s condition.
•The disease/disorder being studied or ex pected progression, signs, or s ymptoms of 090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 91the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that
leads to the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life-threatening
The term “life-threatening” in the definition  of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event thathypothetically might have caused de ath if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_321287], hospi[INVESTIGATOR_125403] e participant has been detained (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_364944]/or treatment that would not have been  appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_364945], the event is 
serious. When in doubt as to whether “hospi [INVESTIGATOR_059]” occurred or was necessary, the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre existing condition that did not worsen from
baseline is not considered an AE.
d.Results in persistent disability/incapacity
•The term disability means a substantial disruption of a person’s ability to conduct
normal life functions.
•This definition is not intended to include  experiences of relatively minor medical 090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 92significance such as uncomplicated headache, nausea, vomiting, diarrhea,
influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening o r result in death or hospi[INVESTIGATOR_364946]. These events should usually be considered serious.
•Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse.
10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF and for reporting serious adverse events on the C linical Trial (CT) Serious Adverse Event
(SAE) Report Form to [COMPANY_007] Safety.  Th ese requirements are delineated for 3 types of
events: (1) SAEs; (2) nonserious adverse events (AEs); and (3) exposure to the investigational product under study during pregn ancy or breastfeeding, and occupational
exposure.
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must be completed in a consistent manner. AEs s hould be recorded using concise medical 
terminology and the same AE term should be used on both the CRF and the CT SAE Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] Safety Within 24 Hours of Awareness
SAE All All
Nonserious AE All None090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-[ADDRESS_455976] under study during pregnancy or breastfeeding, and occupational exposureNone All (and exposure during 
pregnancy [EDP]supplemental form for EDP)
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic reports) related to the event.
•The investigator will then record all relevant AE/SAE information in the CRF.
•It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT SAE Report Form/AE/SAE CRF page.
•There may be instances when copi[INVESTIGATOR_364947]. In this case , all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_346246].
•The investigator will attempt to establish a diagnosis of the event based on signs,
symptoms, and/or other clinical information. Whenever possible, the diagnosis (notthe individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories: 
•Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal 
discomfort and not interfering with everyday activities.
•Moderate: An event that causes sufficien t discomfort and interferes with normal 
everyday activities.
•Severe: An event that prevents normal ever yday activities. An AE that is assessed 
as severe should not be confused with an SAE.  Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes
as described in the definition of an SAE, NOT when it is rated as severe.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 94Assessment of Causality
•The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE.
•A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal rela tionship, rather than a relationship cannot
be ruled out.
•The investigator will use clinical judgment to determine the relationship.
•Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal rela tionship of the event to study intervention 
administration will be considered and investigated.
•The investigator will also consult the investigator’s brochure (IB) and/or product 
information, for marketed products, in his/her assessment.
•For each AE/SAE, the investigator must document in the medical notes that he/she
has reviewed the AE/SAE and has provided an assessment of causality.
•There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the sponsor.
•The investigator may change his/her opi[INVESTIGATOR_9242]-up 
information and send an SAE follow-up report with the updated causality assessment.
•The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.
•If the investigator does not know whether or not the investigational product caused
the event, then the event will be handled as “related to investigational product” for reporting purposes, as defined by [CONTACT_78269].  In addition, if the investigator 
determines that an SAE is associated with study procedures, the investigator mustrecord this causal relationship in the source documents and CRF, and report such an assessment in the dedicated section of the CT SAE Report Form and in accordance with the SAE reporting requirements.
Follow-up of AEs and SAEs
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_941] 090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 95sponsor to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological examinations, or consu ltation with other healthcare professionals.
•If a participant dies during participation in the study or during a recognized
follow-up period, the investigator will provide [COMPANY_007] Safety with a copy of any 
postmortem findings including histopathology.
•New or updated information will be recorded in the originally completed CRF.
•The investigator will submit any updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
•The primary mechanism for reporting an SAE to [COMPANY_007] Safety will be the electronic 
data collection tool.
•If the electronic system is unavailable, th en the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
•The site will enter the SAE data into the electronic system as soon as the data
become available.
•After the study is completed at a given site , the electronic data collection tool will 
be taken off-line to prevent the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off-line, then the site can report this information on a paper SAE form (see next section) or to [COMPANY_007] Safety by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
•Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety.
•In circumstances when the facsimile is not working, notification by [CONTACT_20021] a copy of the CT SAE Report Form sent by [CONTACT_364965].
•Initial notification via telephone does not replace the need for the investigator to
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 9610.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion CriteriaMale participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least [ADDRESS_455977] dose of study intervention :
•Refrain from donating sperm.
PLUS either :
•Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.
OR
•Must agree to use a male condom when engaging in any activity that allows for 
passage of ejaculate to another person. 
In addition to male condom use, a highly effe ctive method of contraception will be
considered in woman of childbearing potential (W OCBP) partners of male participants (refer 
to the list of highly effective methods below in Section 10.4.4 ).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, or a
WOCBP (see definitions below in Section 10.4.3 ).
The investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetectedpregnancy. 
10.4.3. Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, additional evaluation should be considered.
Women in the following categories are not considered WOCBP:
1. Premenopausal female with 1 of the following:
•Documented hysterectomy;090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 97•Documented bilateral salpi[INVESTIGATOR_1656];
•Documented bilateral oophorectomy.
For individuals with permanent infertility due  to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion 
should be applied to determining study entry.
Note: Documentation for any of the above categories can come from the site 
personnel’s review of the participant’ s medical records, medical examination, or
medical history interview. The method of documentation should be recorded in the participant’s medical record for the study.
2. Postmenopausal female.
•A postmenopausal state is defined as age 60 years or older or no menses for 
12 months without an alternative medical cause.
•A high follicle-stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopaus al state in women not using hormonal 
contraception or hormone r eplacement therapy (HRT). 
•Female on HRT and whose menopausal status is in doubt will be required to
use one of the nonestrogen hormonal highly effective contraception methods 
if they wish to continue their HRT during the study.  Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
10.4.4. Contraception Methods
The following contraception methods are be used by [CONTACT_364966]:
Highly Effective Methods That Have Low User Dependency
1. Implantable progestogen-only hormone co ntraception associated with inhibition of 
ovulation.
2. Intrauterine device (IUD).3. Intrauterine hormone-releasing system (IUS).4. Bilateral tubal occlusion.5. Vasectomized partner.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 98•Vasectomized partner is a highly effectiv e contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm hasbeen confirmed. If not, an additional h ighly effective method of contraception
should be used. The spermatogenesis cycle is approximately 90 days.
Highly Effective Methods That Are User Dependent
1. Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation.
•Oral;
•Intravaginal;
•Transdermal;
•Injectable.
2. Progestogen-only hormone contraception a ssociated with inhibition of ovulation.
•Oral;
•Injectable.
3. Sexual abstinence.
•Sexual abstinence is considered a highl y effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliabil ity of sexual absti nence needs to be
evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
One of the following effective barrier methods must be used in addition to the highly 
effective methods listed above that are user dependent:
•Male or female condom with or without spermicide;
•Cervical cap, diaphragm, or sponge with spermicide;
•A combination of male condom with either cervical cap, diaphragm, or sponge 
with spermicide (double-barrier methods).090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 99Collection of Pregnancy Information
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy (EDP) occurs if:
•A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational product; or the female becomes or is found to be pregnant after discontinuing and/or being exposed to the investigational product;
•An example of environmental exposure would be a case involving direct contact 
[CONTACT_4490] a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant and has been exposed to chemotherapeutic products).
•A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed
during his partner’s pregnancy.
If a participant or participant’s partner becomes or is found to be pregnant during the 
participant’s treatment with the investigation al product, the investigator must report this 
information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP supplemental form,regardless of whether an SAE has occurred.  In addition, the investigator must submit
information regarding environmental exposure to  a [COMPANY_007] product in a pregnant woman (eg, a
participant reports that she is pregnant a nd has been exposed to a cytotoxic product by 
[CONTACT_4691][INVESTIGATOR_4598]) to [COMPANY_007] Safety using the EDP supplemental form.  This must be doneirrespective of whether an AE has occurred and within 24 hours of awareness of theexposure.  The information submitted shou ld include the anticipated date of delivery (see 
below for information related to termination of pregnancy).
Follow-up is conducted to obtain general i nformation on the pregnancy and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy until completion (or until pregnancy termination) and no tify [COMPANY_007] Safety of the outcome as a 
follow-up to the initial EDP supplemental form.  In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth.  In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by [CONTACT_4692] (unless preprocedure test findings are conclusive for a congenital anomaly and the findings arereported).
If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly [in a
live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the investigator should follow the procedures for reporting SAEs.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 100Additional information about pregnancy outcome s that are reported to [COMPANY_007] Safety as SAEs
follows: 
•Spontaneous abortion includes miscarriage and missed abortion;
•Neonatal deaths that occur within [ADDRESS_455978]. 
Additional information regarding the EDP may be requested by [CONTACT_456].  Further
follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on 
preterm infants to identify developmental delays). In the case of paternal exposure, theinvestigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that the participant was given the Pregnant Part ner Release of Information Form to provide to his
partner.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 0 1  
 
 
 
 
 
 
 
 
 
  
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page [ZIP_CODE].6. Appendix 6: Liver Safety: Suggested  Actions and Follow-up Assessments
Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by [CONTACT_20023]) are termed “tolerators,” while t hose who show transient liver injury, but adapt
are termed “adaptors.”  In some participan ts, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are "susceptible" to progressive and serious liver in jury, commonly referred to as drug-induced 
liver injury (DILI).  Participants who experience a transaminase elevation above 3 times the upper limit of normal (
×ULN) should be monitored more frequently to determine if they are 
an “adaptor” or are “susceptible.”
In the majority of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede to tal bilirubin (TBili) elevations (>2 ×ULN) by [CONTACT_364967].  The increase in TBili typic ally occurs while AST/ALT is/are still elevated
above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within the same laboratory
sample).  In rare instances, by [CONTACT_364968] i elevations are detected, AST/ALT values might 
have decreased. This occurrence is still rega rded as a potential DILI. Therefore, abnormal 
elevations in either AST OR ALT in addition to TBili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always beconsidered important medical events, even befo re all other possible causes of liver injury 
have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the
participant’s individual baseline values and unde rlying conditions.  Participants who present 
with the following laboratory abnormalities should be evaluated further as potential DILI(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:
•Participants with AST/ALT and TBili basel ine values within the normal range who 
subsequently present with AST OR ALT values >3 
×ULN AND a TBili value
>2 × ULN with no evidence of hemolysis and an alkaline phosphatase value<2
×ULN or not available.
•For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in th e definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
•Preexisting AST or ALT baseline valu es above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is
smaller).
•Preexisting values of TBili above the no rmal range: TBili level increased from 
baseline value by [CONTACT_8895] 1 × ULN orif the value reaches 
>3 × ULN (whichever is smaller).090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-[ADDRESS_455979]/ALT and TBili separated by [CONTACT_726] a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it represents a potential Hy’s law case s hould be reviewed with the sponsor.
The participant should return to the investig ator site and be evaluated as soon as possible,
preferably within 48 hours from awareness of t he abnormal results.  This evaluation should 
include laboratory tests, detailed history, and physical assessment.
In addition to repeating measurements of AS T and ALT and TBili for suspected cases of 
Hy’s law, additional laboratory tests should include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma-glutamyl transferas e (GGT), prothrombin time (PT)/international
normalized ratio (INR), TBA, and alkaline phos phatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial
abnormalities to determine etiology.  A detailed  history, including relevant information, such
as review of ethanol, acetaminophen (either by [CONTACT_20025] a coformulated product in prescription or over-the-counter medications), recrea tional drug, supplement (herbal) use and 
consumption, family history, sexual history, travel history, history of contact [CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potentialoccupational exposure to chemicals, should be collected.  Furt her testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary tract) and collection of serum sample for acetaminophen drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing a s meeting the laboratory criteria of AST/ALT and 
TBili elevation defined above should be considered potential DILI (Hy’s law) cases if noother reason for the liver function test (LFT) abnormalities has yet been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability of all the results of the investigations per formed to determine etiology of the LFT
abnormalities.
A potential DILI (Hy’s law) case become s a confirmed case only after all results of
reasonable investigations have been received and have excluded an alternative etiology.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page [ZIP_CODE].7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as Adverse Events (AEs)
•Marked sinus bradycardia (rate <40 bpm) lasting minutes.
•New PR interval prolongation >280 msec.
•New prolongation of QTcF to >480 msec (absolute) or by ≥60 msec from baseline.
•New-onset atrial flutter or fibrillatio n, with controlled ventricular response rate:
ie, rate <120 bpm.
•New-onset type I second-degree (Wenckebach) AV block of >30 seconds’ duration.
•Frequent premature ventricular comple xes (PVCs), triplets, or short intervals 
(<30 seconds) of consecutive ventricular complexes.
ECG Findings That May Qualify as Serious Adverse Events (SAEs)
•QTcF prolongation >500 msec.
•New ST-T changes suggestive of myocardial ischemia.
•New-onset left bundle branch block (QRS >120 msec).
•New-onset right bundle branch block (QRS >120 msec).
•Symptomatic bradycardia.
•Asystole:
•In awake, symptom-free participants in sinus rhythm, with documented periods 
of asystole ≥3.0 seconds or any escape rate <40 bpm, or with an escape rhythm 
that is below the AV node. 
•In awake, symptom-free participants with atrial fibrillation and bradycardia 
with [ADDRESS_455980] 5 seconds or longer. 
•Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate
>120 bpm.
•Sustained supraventricular tachycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).
•Ventricular rhythms >30 seconds’ duration, including idioventricular rhythm (rate
<40 bpm), accelerated idioventricular rhythm (40< x <100), and 090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
PF-07081532
Protocol C3991002Final Protocol, 16 January 2020
PFIZER CONFIDENTIAL
Page 105monomorphic/polymorphic ventricular tachycardia >100 bpm (such as torsades de 
pointes).
•Type II second-degree (Mobitz II) AV block.
•Complete (third-degree) heart block.
ECG Findings That Qualify as Serious Adverse Events
•Change in pattern suggestive of new myocardial infarction.
•Sustained ventricular tachyarrhythmias (>30 seconds’ duration).
•Second- or third-degree AV block requiring pacemaker placement.
•Asystolic pauses requiring pacemaker placement.
•Atrial flutter or fibrillation with rapid v entricular response requiring cardioversion.
•Ventricular fibrillation/flutter.
•At the discretion of the investigator, any arrhythmia classified as an adverse
experience.
The enumerated list of major events of potentia l clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and [COMPANY_007] study team, and not to be 
considered as all inclusive of what  to be reported as AEs/SAEs.090177e1995f4769\0.1\Draft\Versioned On:16-Feb-2022 06:37 (GMT )
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 0 6 1 0. 8. A p pe n di x 8: Ab bre vi ati o ns 
T he f oll o wi n g is a list of a b br e v ia ti o ns t hat m ay be use d i n t he pr ot oc o l. 
A b bre vi ati o n Ter m 
A bs Abs olute 
A E Ad ver se eve nt 
Ae2 [ADDRESS_455981] q ua ntifia b le c o nce nt rati o n 
 
AUC4 Are aun de r t he cur ve o ver 4h o u rs 
A U C 24 Are au n de r t he c o nce ntrati o n -ti me cur ve o ver 2 4 h o u rs
A U C i nf Are a u n der t he c o nce ntrati o n -ti me c ur ve t o i nfi nit y 
AV Atri o ve ntr ic ular 
-h C G Be ta - h u ma n c h ori o nic g o na d otr o p i n 
B MI Bo d yma ss i n de x 
B P Blo o d pr ess ure
Bp m Beat sper m in ute 
BUN Bl o odur ea nitr o ge n 
C F R C o de of Fe d er al Re g ula ti ons 
 
CI OMS Council f or Int er n ati o nal Or ga ni zati o ns ofMe dical Scie nces 
C K Creatine k inase 
CLr Re nal cleara nce 
Cma x Ma x i m um o bser ve d c o nce ntrat io n 
C O 2 Car b o n di o xi de ( bicar b o na te) 
C O N S O R T Co ns oli d ate d Sta n d ar ds o fRe p or ti n g Trials
C R F Case re p ortf or m 
C R O Contr act rese ar ch or ga n izati o n 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI 
P F -[ADDRESS_455982] imate d gl o me r u lar fi ltrati o n rate 
E M A E u ro pe a n Me dici nes A g e nc y 
EU E ur o pe an Uni o n 
E u dra C T Eur o pea n Cli nical Trial sDat a base 
FS B G Fi n g ersti c k bl o o d gl uc ose 
F S H Foll icle -sti m ula tingh or m o ne 
F U F oll o w -u p 
G C P G o o d C li nical Practice 
G F R Gl o mer u lar filtrati o n rat e
G G T Gam m a-gl uta m yl  tra nsf erase 
GL P -1 Gl u ca g o n -li ke pe pt i de -1
G L P-1R Gl u cag o n -like pe pt ide -1 rece pt or 
Horhr Hour
H b A 1c Gl y cate d he m o gl o bi n 
H B c A b He p atit is B c o re a n ti b o d y
H Bs A b Hepat it is B s urfac eantibo d y
H Bs Ag He pati ti sB s urface a nti gen
HCV A b He p atit is C a nti b o d y 
HI P A A Healt h I ns ura nc eP orta bili ty a n dAcc o u nt a bi lit y A c t
HI V Hu ma n i m m u n o d eficie ncyvir us
H R T Hor m one re p lace m e ntthera p y 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI C CI 
C CI 
C CI C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 0 8 A b bre vi ati o n Ter m 
IB In vesti gat or’s b r o ch ur e
I C D Inf or med conse nt d o cum e nt 
I C H I nter na ti o n al C o u nci l f or Ha rm o nisati o n 
I D Identificati o n 
I N D In ves ti gati o na l ne w dr u g applic ation
I N R Int er nati o nal n or ma lize d rati o 
IP In vesti g ati o nal pr o d uct 
IPma n ual In ve sti gati o na l pr o d uct ma n ual 
I R B Insti t u tiona lre v ie w b o ar d 
I R T Intera cti ve res po n setec h n ol o g y
I U D Intra uteri ne de vic e
I U S Intra u teri ne hor m o n e-re leasi n g s ys te m 
IV Intr ave n o us 
IWR Int eract i ve W eb-base d res p o n se
K2E D T A Di p o tassi u m et h y le ne d i a mi ne tetraacetic ac i d 
K g Kil o g ra m 
L B B B Lef t b u n dle bra nc h bl oc k
LFT Li ve r funct i o n test 
M A D Mul ti p leas ce n di n g dose 
 
M C H Mea n c o rp usc ular hem o g l o bi n 
MCH C Mea n c or p usc ul arhe m o g l o bi n co nce ntra ti o n 
M C V Mea n c o r p usc ular v ol u me 
M E N [ADDRESS_455983] o m etype 2 
Mg/ d L Milli gra m( s) per decilite r
µmol/ L Mic romole perli ter 
M D RD Mo d ific ati o n of diet i n r enal di sea se 
mi n Mi n ut e or mi nim u m
Msec Milli sec o n d 
MTC Me d ulla ry t h yr oi d ca ncer 
M T D Maxi m u m t olerate d d ose 
N/ A Not a p pl ica ble 
N N u m ber 
N C N ot calc u late d 
N H P No n -hu m an pr imate 
nM Nan o m olar 
NOA E L No-obs erve d -ad vers e-effec t le vel 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI C CI 
C CI 
C CI 
C CI 
P F -[ADDRESS_455984] u g s
 
P C D Pri mar y c o m p leti o n da te 
P G x Pha r mac o g e n o m ic(s) 
PI [INVESTIGATOR_364948] i n vest i g at or 
PK Phar mac o k i ne tic( s) 
P T Pr o thro m bi n ti me 
 
PTT Partial t h r o m b o plasti n ti me 
P V C Pre mat ure ve ntric ular c o n tr acti o n/ c o m ple x 
Q D Dail y 
Q T D ur ati o n of v e n tric ular de p ol ariz ati o n a n d s u bse q ue nt 
re p o la rizati o n. D ura ti o n resi d es bet we e n be gi n ni n g of Q R S c o m ple x 
t o endof t he T wa ve. 
Q Tc Corr ecte d Q T
QTcF Correc te d Q T (Fri d ericia met h o d) 
Qua l Qual itati ve 
 
R B C Re d bl o o d ce ll 
S A E Seri o us a d ve rs ee ve n t
S A P Statist ical a n al y sis p lan
S Cr Ser u m cr eati ni ne 
S D Sta n dar d de v iati o n
S G L T [ADDRESS_455985] io n 
t½ Half l ife
T 2 D M Ty pe 2 di a bet es me llit us 
T B D T o be deter mi ne d 
T B A Total bile aci d s
T Bili Total bil ir u bi n0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI 
C CI C CI C CI 
C CI 
P F -[ADDRESS_455986] oca n na bi n ol
Tma x Ti me t o ma xi m u m conc e n tra ti o n
TS H Th y roi d sti m ulati n g h or m o ne 
T Z D s T hi az o li d ine d iones
U L N Up p er li m it of n or mal 
US U n it e d States 
 
WBC White bl o o d cell 
W O CB P Womanofc h il d beari n gp ote ntial 
W O N C B P Womanofn o n -chil d b eari n g p ot e ntial 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI C CI 
C CI 
C CI 
P F -[ADDRESS_455987] JJ , K n u htse n S,et al. Gl uc a g o n -li ke pe pt ides G L P- 1 a n d G L P- 2, 
pre di cte d pr o d ucts o f t he gl u ca g o n g ene, are se crete d se paratel y f r o m pi g s mall i n tes ti n e 
b ut n ot pa ncreas. En d ocri n ol o g y 1 9 8 6; 1 1 9( 4 ): 146 7 - 7 5. 
2. Kr e y ma n n B, Wil li a ms G, G hatei M A , e t al . Gl uca g o n-li ke pe pt i de - 1 7- 3 6: a
p h ys i o lo g ical i ncre ti n i n ma n. La n cet 1 9 8 7; 2( 8 5 7 1): 1 3 0 0- 4. 
3. Na uc k M A, Nie der eic h h olz U, Ettler R ,et al. Gl uca g o n -li ke pe pti de 1 i n hi b iti o n of 
gastr ic e m pt yi n g o ut w ei g hs it s i n s ul i n otr o pic eff ec ts i n hea lt h y  h u ma ns. Am J P h y si ol 
1 9 9 7; 2 7 3( 5 ): E [ADDRESS_455988] 1 9 9 8 ; 1 0 1( 3): 5 1 5- 2 0. 
5. I D F D ia betes Atl as 8 t h E di ti o n:. h tt p: // w w w.i df. or g/ dia b et es atl as .
6. Me n ke A , C as a gra n de S, Geiss L,  et al .Pre val e nc e of a n d Tre n ds i n Di a betes A m o n g 
Ad ults int h e U ni te d States , 1 9 8 8- 2 0 1 2.  J A M A 2 0 1 5; 3 1 4 ( 1 0) : 1 02 1. 
7. H u F B . Gl o ba li zati o nof di a be te s: t he role o f d iet, l ife st yl e a n d ge nes . Di a be tes C are 
2 0 1 1 ; 3 4( 6) : 1 2 4 9 - 5 7. 
8. De Fr o nz o R A .Fr o m t he tri u m vi rate t o t he o m ni o us oc tet: a ne w p ar a di g m for t he 
treat me nt o ft y pe 2dia be tes melli t us. Dia betes 2 0 0 9; 5 8 ( 4) : [ADDRESS_455989] icati o ns of t y pe2 dia b etes ( U K P D S 3 5): pr os pecti ve 
o b se r v ati o nal s tu d y . B M J 2 0 0 0; 3 2 1( 7 2 5 8) : 4 0 5- 1 2. 
1 1. A merica n Dia be tes Ass ociati o n. P har ma c ol o g ic Appr oa c h es t o Gl y ce mic T re at m ent: 
St a n dar ds of Me dical Care i n Dia betes — 2 0 1 9 A meric a n D ia betes Ass oci at i o n .Dia be te s
Car e 2 0 1 9 J a n; 4 2 (S u p ple m e nt (S u p pl .1): S 9 0- S 1 0 2 .
.
1 4. Pe tri K C C ,I n g werse n S H, Fli nt A, e t al. E x p os ure -r es p o nse a nal ys is f or e val uati o n o f
se ma gl uti de d ose le vels i n t y pe 2 dia betes. Dia be tes O bes Meta b 2 0 1 8; 2 0( 9): 2 2 3 8 - 4 5. 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 
C CI C CI 
P F -0 7 0 8 1 53 2 
Pr ot oc ol C 3 9 9 1 0 0 2 
Fi nal Pr ot oc ol , 1 6 Ja n uar y 2 0 2 0 
P FI Z E R C O N FI D E N TI A L 
Pa ge 1 1 2  
 0 9 0 1 7 7 e 1 9 9 5f 4 7 6 9\ 0. 1\ Dr aft\ V er si o n e d O n: 1 6- F e b- 2 0 2 2 0 6: 3 7 ( G M T) C CI 